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Summary 
Intestinal homeostasis is maintained by the dynamic interplay between the gut microbiota 
and the host immune system. Alterations in the composition and function of the gut 
microbiota have been associated with a wide range of human disease including 
inflammatory bowel disease and rheumatoid arthritis. Diverse microbial signatures within the 
intestinal microbiota have been associated with increased susceptibility to intestinal 
inflammation, but whether these candidate microbes actively modulate host phenotypes is 
frequently not known. Metabolites produced through microbiota activity have recently been 
linked as mediators to distinct intestinal and systemically immune-related disorders. 
The role of members of the Prevotella genus within the intestinal microbiota and their effects 
on the host is not completely understood and somewhat conflicting interpretations have 
been reported. Whereas association with plant-rich diet and improved glucose metabolism 
suggested Prevotella spp. are beneficial for the host, their increased relative abundances in 
microbial ecosystems at multiple body sites have been associated with diverse diseases. 
Yet, whether Prevotella spp. actively contribute to the development of these diseases is not 
known. The detailed investigation of the immunomodulatory properties of Prevotella spp. 
has been prohibited by the poor characterization of Prevotella species and high strain 
diversity, as well as the lacking availability of diverse intestinal Prevotella isolates. 
In the present work, we isolated three novel intestinal Prevotella species from mice prone to 
intestinal inflammation. Characterization of the impact of Prevotella colonization on the 
interplay between host and the microbiota during intestinal homeostasis and inflammation 
was performed using P. intestinalis, which among the three novel species shared the 
highest similarity to the predominant human gut Prevotella species - P. copri. We identified 
that colonization by this novel member of the Prevotella genus significantly decreased the 
production of the bacterial fermentation product SCFAs and the immunomodulatory cytokine 
IL-18, which was associated with an increase in the severity of intestinal inflammation. Our 
findings suggested that Prevotella-mediated intestinal injury may be influenced via different 
pathways, yet the ability to ameliorate Prevotella-induced disease severity by 
supplementation of IL-18 suggested that remodeling of the microbial metabolome and 
specifically SCFA production may be the dominating pathomechanism. Finally, the 
consequences of modulation of SCFA production in the intestine by Prevotella spp. may 
have far-reaching consequences for the host, as SCFA have immunomodulatory effects in 
distant sites such as the liver, bones or the brain. 
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Zusammenfassung 
Die intestinale Homöostase wird durch dynamische Wechselwirkungen der Darmmikrobiota und 
dem Immunsystem aufrecherhalten. Verämderungen bei der Zusammensetzung und Funktion 
der Mikrobiota wurden mit diversen Krankheitsbildern im Menschen assoziiert, wie entzündliche 
Darmerkrankungen und rheumatoider Arthritis. Auch wenn diverse mikrobielle Signaturen mit 
einer erhöhten Anfälligkeit für Darmentzündungen assoziiert werden konnten, bleiben die 
ursächlichen Mikroben, welche die auftretenden Phenotypen aktiv modulieren, unbekannt. 
Kürzlich konnten von der Mikrobiota produzierte Metabolite als Mediatoren für 
Darmentzündungen und systemische Immunerkrankungen identifiziert werden. 
Die Rolle von Bakterien aus dem Prevotella Genus und ihre Effekte auf den Wirt im Kontext von 
Darmentzündungen führte zu gegensätzliche Interpretationen. Zum einen wurde eine erhöhte 
Anzahl an Prevotella spp. mit einer pflanzenreichen Ernährung und einem verbesserten 
Glucose-Metabolismus assoziiert, zum anderen wurde Prevotella spp. in mikrobiellen 
Gemeinschaften mit diversen Krankheiten in Verbindung gebracht. Ob Prevotella spp. aktiv bei 
der Entstehung dieser Krankheiten beiträgt ist nicht bekannt. Eine detaillierte Untersuchung der 
immunmodulatorischen Eigenschaften von Prevotella spp. wurde bisher durch mangelnde 
Charakterisierungen der Prevotella-Spezies, die große Vielfalt der bekannten Stränge und die 
fehlende Verfügbarkeit verschiedener Prevotella-Isolate des Darmes erschwert. 
In dieser Arbeit wurden drei neue intestinale Prevotella Spezies aus Mäusen isoliert, die anfällig 
für intestinale Entzündungen sind. Die Rolle von Prevotella beim Wechselspiel zwischen Wirt 
und der Mikrobiota bei intestinaler Homöostase und Entzündung wurde mit dem Isolat 
P.intestinalis untersucht, welches von den neu isolierten Spezies die höchste Ähnlichkeit zu der 
im humanen Darm dominanten Prevotella Spezies (P. copri) aufweist. Es konnte gezeigt 
werden, dass eine Besiedlung mit dieser P. intestinalis sowohl die bakterielle Produktion von 
kurzkettigen Fettsäuren (SCFAs) als auch die Bildung des immunmodulatorischen Zytokins IL-18 
signifikant verringert, was wiederrum mit einem erhöhten Schweregrad einer intestinalen 
Entzündung assoziiert wird. Dies impliziert, dass die durch Prevotella mediierte intestinale 
Enzündung durch unterschiedliche Signalwegen beeinflusst werden kann. Da die Prevotella-
induzierte Krankheitsschwere durch eine Supplementierung von IL-18 gelindert werden kann, 
stellt die Veränderung des mikrobiellen Metaboloms und vor allem der Bildung der SCFAs 
möglicherweise den dominierenden Pathomechanismus dar. Da SCFAs immunmodulatorische 
Effekte an unterschiedlichsten Stellen des Körpers wie Leber, Knochen oder Gehirn haben, hat 
die Modulierung der SCFA-Produktion im Darm durch Prevotella spp. damit letztendlich 
vermutlich weitreichende Folgen für den Wirt. 
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Introduction 
 
1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) comprises a group of intestinal disorders that cause 
prolonged inflammation of the digestive tract. Most cases of IBD are classified as either 
ulcerative colitis (UC) or Crohn’s disease (CD). While ulcerative colitis generally affects the 
innermost lining of the intestinal wall and is characterized by continuous inflammation of the 
colon and rectum, Crohn’s disease can manifest as ulcerations and damage of all layers of 
the intestinal wall of any part of the gastrointestinal tract1. IBD was once a very rare 
disorder, and its incidence only began to rise in the second half of the 20th century. In time-
trend analyses, 75% of CD studies and 60% of UC studies showed increased incidence 
rates over times2 with estimated 53,000 new cases of CD and 123,000 new cases of UC 
each year in Europe3. The highest reported prevalence of IBD is in Europe (UC, 505 per 
100,000 persons; CD, 322 per 100,000 persons) and North America (UC, 249 per 100,000 
persons; CD, 319 per 100,000 persons. Cases are much less common in non-Western 
nations, although IBD has emerged in newly industrialized countries in Asia, South 
America and the Middle East and has evolved into a global disease with rising prevalence 
in every continent4. 
Although the etiology of IBD in a classic sense remains unknown, multiple hereditary, 
environmental, and lifestyle factors are thought to influence the pathology of the disease. It 
is now widely recognized that the cause of IBD originates in an extremely complex 
interaction of aberrant immune responses to members of intestinal microbes, further 
complicated by genetic and environmental factors5. Importantly, none of these factors is 
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likely to cause the disease alone and the ongoing research aims to solve how these factors 
individually or collectively contribute of the disease development. 
1.1.1 Genetic factors in IBD 
The fastest progress in understanding the IBD pathogenesis has been done in the field of 
genetic studies. Genome-wide association studies (GWAS) have revealed over 230 IBD 
susceptibility loci, substantially more than reported for any other complex disease6. Some of 
the most prominent genetic associations to IBD are the genomic regions containing 
nucleotide oligomerization domain 2 (NOD2), autophagy-related genes, multiple genes 
involved in T helper (Th) 17 cells and interleukin (IL)-23 signaling pathway as well as 
variants in IL10 loci. NOD2, an intracellular sensor which stimulates an immune reaction 
upon microbial recognition, was the first identified CD susceptibility gene7,8. Genetic 
analyses in IBD patients reported single nucleotide polymorphisms (SNPs) in two genes 
involved in autophagy, autophagy related 16-like 1 (ATG16L1), and immunity-related 
GTPase M protein (IRGM)9–12. Autophagy not only clears intracellular components but also 
removes invading intracellular bacteria. Furthermore, a significant association between IBD 
and the IL23R gene has been described13. The IL23R gene encodes a subunit of the 
receptor for the proinflammatory cytokine IL-23, a molecule involved in the generation of 
Th17 cells. Among identified susceptibility loci for IBD, there are also genes related to the 
inflammasome components like members of the nucleotide binding domain and leucine-rich 
repeat-containing proteins NLR family, i.e. NLR family pyrin domain containing 3 (NLRP3), 
including downstream related protein IL-1814,15. Recently, another NLR protein, NLRP6, has 
been found to be highly expressed in colon biopsies from active ileal CD patients 16. Both 
NLR proteins are intracellular receptors that are directly or indirectly activated by microbial 
products and have been shown to play an important role in intestinal inflammation in mouse 
models17–19. 
Interestingly, not all genetic susceptibilities present the same risk across the world. It has 
been noted that, for example, ATG16L1 gene represents a higher risk for CD in the 
population of European descent, but not in Asian people. Notably, in Asia only 3% of people 
with IBD have a close relative with the disease, compared with 15% of individuals in the 
Western world20. Furthermore,  studies in monozygotic twins showed that the concordance 
rate for UC is 10–15% compared with 30–35% in CD21,22. These observations suggest that 
genetic factors are responsible for only a part of the overall disease variance. In addition, 
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most of the evidence related to a possible genetic cause point to pathways essential for 
intestinal homeostasis, innate and adaptive immune regulation and microbial defense. 
These elements support the hypothesis that microbial interactions with the immune system 
play a key role in IBD. The interplay between intestinal microbes and mucosal immune 
system in the intestine is the focus of the present work and is reviewed in more details 
below. 
1.1.2 Environmental triggers in IBD 
Multiple environmental factors have been found to contribute to the development of IBD23. 
Knowing that the prevalence of IBD has been changing in the last 20 years and that the 
incidence is on the rise in developing countries, westernization of lifestyle and 
industrialization have been implicated as major factors24. This includes changes in hygiene, 
diet, and medical treatments. Among medical treatments, oral contraceptives, post-
menopausal hormone replacement, aspirin, NSAIDs, and antibiotics have been implicated in 
increased risk of CD or UC25. Most of these factors are known to influence the composition 
of the intestinal microbial communities, making it unclear whether they are a primary or 
secondary event26. 
One of the most studied environmental triggers for CD and UC is smoking. Several studies 
showed that smoking increases the risk of developing CD by two fold, while it has protective 
effects on UC. Regardless of strong epidemiological data, the reasons for the opposite 
effects of smoking on CD and UC remain unclear and require further investigation25,27,28. 
1.2 The intestinal epithelial barrier  
It has been hypothesized that IBD arises from dysregulated immune responses towards the 
intestinal microbial communities1,29. To prevent aberrant immune response, intestinal 
epithelial cells serve as a physical and biochemical barrier that separates the host tissue 
and commensal bacteria necessary to maintain the intestinal homeostasis. Therefore, 
impairment of the barrier functions is thought to promote intestinal inflammation IBD30. 
Being exposed to numerous antigens from potentially harmful microbes but also harmless 
dietary components, the intestinal mucosal immune system evolved a wide range of defense 
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strategies to monitor the gastrointestinal tract for the presence of pathogens, while tolerating 
trillions of commensal bacteria. In the last two decades, it became evident that the microbial 
communities in the intestine are not just a bystander, but they play a fundamental role in the 
induction, education, and function of the mucosal but also systemic host immune system31. 
This continuous interaction starts already in the womb, intensifies after birth and is dynamic 
throughout life thereby continuously shaping the immune response32. The biggest 
contribution to our knowledge about the importance of the microbiota in shaping host 
immunity comes from germ-free (GF) models, as they display an ‘underdeveloped’ innate 
and adaptive immune system: reduced expression of antimicrobial peptides, reduced IgA 
production, reduced T cell diversification and recruitment resulting in increased susceptibility 
to microbial infections33–36. Conversely, the host immune system influences the microbiota 
composition through various mechanisms, as seen in several immune deficiencies37–39. 
These strong interconnections between the microbiota and the intestinal immune system 
make studying one without the other rather difficult. In general, these findings demonstrate 
that the microbiota and the host immune system have a complex, dynamic, and reciprocal 
dialogue.  
The single layer of intestinal epithelium plays a central role in maintaining the homeostasis 
in the intestine. It positions itself as a barrier between the vast number of microbial species 
and their products and the mucosal immune system, thus minimizing their contact and 
promoting the symbiotic relationship. However, intestinal epithelial cells (IECs) are more 
than just a physical barrier. Besides their importance in nutrient absorption, IECs preform 
signal-transduction functions by sensing bacterial products through innate immune receptors 
and directing an appropriate immune response in the lamina propria (LP). An immune 
response is triggered as a reaction to numerous endogenous damage-associated molecular 
patterns (DAMPs) and microbe-associated molecular patterns (MAMPs), which include 
ligands from non-pathogenic microbes of the microbiota as well40. MAMPs are recognized 
by a range of pattern recognition receptors (PRRs) expressed in IECs and wide range of 
immune cells, such as Toll-like receptors (TLRs), nucleotide-binding domain and leucine-rich 
repeat containing receptors (NLRs), retinoic acid-inducible gene (RIG) -I like receptors 
(RLRs)41. 
Stem cells within the crypt of the intestinal epithelium generate multiple IEC lineages with 
distinct functions, including absorptive enterocytes (small intestine) and colonocytes (colon), 
enteroendocrine cell, secretory goblet cells and Paneth cell42. Goblet cells form a physical 
and chemical barrier by producing a two-tiered mucus layer that covers the intestinal 
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epithelium and restricts bacterial penetration. While the inner layer is densely packed, firmly 
adherent to the epithelium and devoid of bacteria, the outer layer is more loosely attached 
and it provides a niche for luminal bacteria that use oligosaccharides from mucin as an 
energy source43. Goblet cells can also produce antimicrobial peptides (AMPs). Paneth cells 
are located in the crypts of the small intestine and are contributing to the innate immune 
response by secreting AMPs in reaction to resident microbes or invading pathogen in the 
lumen. The AMPs produced in the intestines include the β-defensins and cathelicidins 
produced by colonocytes, α-defensins, lysozyme, phospholipase A2, and RNases produced 
by Paneth cells, while C-type lectins are produced by most IEC lineages44. Some of these 
AMPs, such as α-defensins, are expressed constitutively, while others are secreted upon 
sensing of distinct MAMPs, frequently derived or also present in commensal bacteria. For 
instance, it has been shown that lectins, such as regenerating islet-derived protein (Reg)IIIγ, 
RegIIIβ, and resistin-like molecule (RELM) β, are induced by microbial signals in a TLR-
MyD88 (myeloid differentiation primary response protein 88)-dependent manner45. Another 
study showed that intestinal AMP expression, specifically Retnlb, Ang4, and Itln1, is 
regulated by inflammasome-derived IL-1846. Under homeostatic conditions, IEC represent a 
major source IL-1847 and several studies have suggested IL-18 is a key mediator of 
intestinal homeostasis and inflammation. However, seemingly opposing results have been 
reported, suggesting both beneficial and detrimental properties of IL-18 in the intestine48,49. 
Most recent reports will be discussed in detail in the following section.  
Taken together, the intestinal epithelium represents not only a physical and chemical barrier 
but as well is an important mediator of the dialog between the intestinal microbes and the 
host immune system by the production of proinflammatory mediators, which regulate the 
immune responses and promote the maintenance of intestinal homeostasis. 
1.2.1 Role of interleukin-18 in the intestine: friend or foe? 
Interleukin-18 (IL-18) is a member of the IL-1 family of cytokines50. Similar to IL-1β, IL-18 is 
initially synthesized intracellularly as an inactive precursor where it remains51. Processing of 
the IL-18 precursor into an active mature form is performed by the intracellular cysteine 
protease caspase-1. Comparable with the processing of IL-1β, autocatalytic cleavage of 
inactive pro-caspase-1 first generates active caspase-1 upon assembly of distinct 
inflammasome complexes, including nucleotide-binding domain and leucine-rich repeat 
pyrin containing proteins (NLRPs) and absent in melanoma 2-like receptors (ALRs, AIM2-
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like receptors) 52. Despite similarities, the biology of IL-1β and IL-18 is diverse. Interestingly, 
while gene expression of IL-1β in hematopoietic cells is absent in during steady state 
(healthy humans and mouse), the IL-18 precursor is constitutively present in nearly all 
epithelial cells and blood monocytes51,53. IEC have been shown to represent a major source 
of IL-18 in mice47. 
In the last two decades, numerous studies have shown that IL-18 plays an import role in 
intestinal inflammation, however seemingly opposing results have been reported. Genome-
wide association studies have revealed a number of polymorphisms associated with disease 
susceptibility, including the association of mutations within the IL18R1-IL18RAP locus with 
both adult and severe early-onset IBD54,55. Furthermore, intestinal biopsies from IBD patients 
were characterized by increased concentrations of IL-18 produced by both IECs and 
macrophages56. In addition, a number of studies have used IL-18-deficient mice or 
neutralization of endogenous IL-18 and demonstrated its pro-inflammatory role in driving the 
intestinal inflammation57,58. These data suggested that neutralization of IL-18 would have 
beneficial effects in ameliorating the inflammation. However, data associating 
polymorphisms in the NLRP3 region with increased susceptibility to CD questioned this 
hypothesis15. Interestingly, functional studies in mice demonstrated that the deletion of the 
NLRP3 inflammasome, which consequently resulted in decreases of IL-18 and IL-1β, 
increased the susceptibility to intestinal inflammation19. The same study showed that 
administration of IL-18 could reverse the disease.  
In the past years, the influence of alterations with the microbiota composition on disease 
modulation and phenotypic discrepancies have been observed in numerous experimental 
animal models59,60. Specifically, several studies have addressed in the recent years the role 
of IL-18 in the intestine considering the influence of the microbiota and excluding its effects 
by microbiota normalization. It has been shown that caspase-1 and IL-18 exacerbate 
intestinal inflammation due to impaired repair processes61,62. In contrast, it has been 
demonstrated that deficiency of NLRP6 results in reduced IL-18 levels and microbial 
dysbiosis, which consequently leads to increased susceptibility to intestinal inflammation18. 
Microbial dysbiosis was suggested to arise from decreased IL-18 production and AMP 
levels, which are modulated by microbiota-associated metabolites taurine and distinct 
polyamines46. Several of these studies showed that supplementation of IL-18 ameliorates 
the intestinal inflammation in the dextran sodium sulfate (DSS) colitis model. Interestingly, 
recent work showed that also short-chain fatty acids (SCFA) have the capacity to alter the 
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levels of IL-18 production63. They suggested that IL-18 production, stimulated by SCFA, 
promotes epithelial barrier integrity and regeneration. 
To explain these differences it has been proposed that IL-18, since constitutively expressed 
in the intestinal epithelium, has a protective role by contributing to the maintenance of the 
intestinal barrier by enhancing the regeneration of the damaged epithelium. After damage to 
the barrier, the microbial products stimulate macrophages in the lamina propria and 
excessive caspase-1 dependent processing of IL-18 results in inflammation, suggesting the 
cellular source might be of crucial importance for the observed opposing effects49. However, 
this has not yet been proven experimentally. Moreover, the earlier analysis suggested IL-18 
is cytoprotective in the early stages of IBD, whereas chronic production exacerbates the 
disease64. In addition, it has been discussed that IL-18 ameliorates the inflammation in 
innate colitis induced by intestinal injury (i.e. DSS), whereas it exacerbates the disease in T-
cell dependent colitis i.e. 2,4,6-trinitrobenzene sulfonic acid (TNBS) by promoting IFN-γ 
production in T cells65,66. However, another potential explanation may be that the 
composition of the gut microbiota determines which immune pathway is activated and the 
susceptibility to the diseases, not only the model of colitis used67.  
In summary, despite great efforts to understand the role of IL-18 in intestinal inflammation, 
its particular role in IBD still remains controversial. Understanding the complex interplay 
between the IECs, microbiota and their metabolites, and the immune system that defines 
the balance of IL-18 in the intestine might be crucial for differentiating its protective and 
detrimental effects on the host. 
1.3 Intestinal immune defense 
Along with AMPs, secretion of immunoglobulin (Ig) A by plasma cells is additionally 
reinforcing the intestinal barrier against invading microbes. Gut plasma cells that produce 
IgA can be generated in T cell-dependent and T cell-independent mechanisms. While 
enteric pathogens have been known to induce high affinity T cell-dependent, pathogen-
specific IgA, commensals induce IgA of low affinity and specificity68,69. Some commensal 
bacteria, such as segmented filamentous bacteria (SFB) and Mucispirillum spp., that 
colonize the inner mucus layer induce high-affinity T cell-dependent IgA response69,70. It has 
been suggested that intestinal bacteria that are highly coated with IgA have the potential to 
promote inflammation. Palm et al. showed that colitogenic intestinal communities display an 
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increase in the percentage of IgA-coated (IgA+) bacteria. Sequencing of these bacteria 
found Prevotellaceae, Helicobacteraceae, and segmented filamentous bacteria (SFB) to be 
among the highly coated ones69. Moreover, in the same study transferring the IgA+ bacteria 
from IBD patients to mice exacerbated intestinal inflammation in the animal model of IBD. 
The intestinal barrier is additionally complemented by cells of innate and adaptive immune 
system. Myeloid antigen-presenting cells (APCs) of the intestine are a heterogeneous 
population consisting of dendritic cells (DCs) and macrophages. Like in most tissues, 
intestinal macrophages have essential phagocytic and bactericidal activities that help to 
maintain the intestinal homeostasis. Located in the proximity to high numbers of luminal 
bacteria and antigens, macrophages are a part of first-line defense when the epithelium 
barrier fails due to an infection or an injury71. As the intestinal macrophages are unable to 
proliferate, they are derived from circulating monocytes, which are attracted in steady state 
and during inflammation to the mucosa, where they further differentiate. It has been shown 
that after differentiation in the steady state, resident macrophages have downregulated 
expression of innate receptors for lipopolysaccharide (LPS) - CD14 and IgA and decrease 
the production of pro-inflammatory cytokines72. Hyporesponsiveness of intestinal 
macrophages has been linked to specific microbial metabolites, namely SCFAs73. Such 
regulation of immune responses has an important function in promoting tolerance and 
preventing aberrant inflammatory responses. 
Intestinal dendritic cells are the central player monitoring the environment, responding to 
distinct stimuli, and linking the innate and adaptive immune responses. DC sample antigen 
from transcytosed bacteria in the Payer´s patches or directly from the lumen and present 
them to naive T cells in mesenteric lymph nodes (MLN)74. Whether the DCs will mount a 
tolerogenic or inflammatory response depends on epithelial-derived factors and bacteria-
derived products. These factors together determine the fate of naive CD4+ T helper (Th) 
cells during priming in MLN75.  
CD4+ T cells are a principal component of the adaptive immune system. In the intestine, 
CD4+ T cells are mostly located in the lamina propria. Once stimulated, naive CD4+ T cells 
can differentiate into four major subtypes: T helper 1 (Th1), Th2, Th17, or regulatory T cell 
(Treg), which can be distinguished based on their expression of various transcription factors 
and cytokines. For example, Th1 cells are critical for the host defense against intracellular 
microbial infection, while Th2 cells play an important role in eliminating parasite infections. 
Regulation and balance between the CD4+ T cells subtypes have been shown to be 
important for maintenance of the intestinal homeostasis. Uncontrolled Th responses can be 
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pathological, as the Th1 and Th17 responses have been linked to autoimmune diseases, 
while the Th2 response has been associated with allergic reactions76. In contrast, Tregs 
promote anti-inflammatory response and are a key mediator of immune tolerance. 
Dysfunction of Tregs can lead to exacerbated inflammation and autoimmune disorders77. 
Interestingly, individual members of intestinal microbial communities have been found to 
shape different aspects of immune responses and their role and examples are discussed in 
more detail in section “1.5 Intestinal Commensals as Immune Modulators”. 
1.4 The intestinal microbial community  
The microbial communities of the intestinal tract of vertebrates are composed of bacteria, 
viruses, eukaryotes, archaea, and fungi, which are collectively referred to as the 
“microbiota”. Distinct microbial communities can colonize all epithelial surfaces, but the 
intestinal bacterial members represent the densest and metabolically active community78. 
Recent large studies characterizing microbial communities that inhabit the human body 
estimated that over 1,000 bacterial species can be found in the intestine, of which the most 
abundant are Firmicutes, Bacteroidetes, and Actinobacteria, whereas Proteobacteria, 
Fusobacteria, Cyanobacteria, and Verrucomicrobia are less represented78,79. The microbiota 
composition in every individual is influenced partly by the host genotype and physiology, and 
predominantly by distinct environmental factors, including dietary habits and medications 
(e.g., antibiotics)80,81. Even though studies noted that there is a substantial inter-individual 
variability in the gut microbiota composition in healthy individuals, metabolic functionality is 
rather conserved between groups of studied individuals because many biochemical 
pathways are redundant between alternative members of the microbiome. 
For many years bacteria have been classified either as a “commensal” or a “pathogen”, 
depending on their relationship with the host. However, even though members of the 
microbiota are often referred to as commensals, the form of the crosstalk can vary. Many of 
the microbes found in the gut coevolved with the host and developed beneficial mutualistic 
relationships (Mutualist), while others live in association with a host without obvious benefit 
or harm to either member (Symbiont). Interestingly, there are also members of indigenous 
microbiota that usually do not cause a disease but can exploit disrupted homeostasis and 
exert pathogenic effects on the host. For these microorganisms, the term pathobiont has 
been proposed31,74. Specifically, the term “pathobionts” has been coined to distinguish them 
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from classical acquired opportunistic pathogens. Additionally, commensal bacteria that have 
immunomodulatory properties impacting the host´s immune system, but are not associated 
with a disease, have been referred to as “autobionts”82. Clearly, the terminology used to 
describe the members of the intestinal microbiota based on their relationship with the host 
and functional properties is still evolving.  
It has been by now widely acknowledged that the gut microbiota confers many benefits to 
the host by performing a wide range of metabolic functions. These include food digestion, 
bioconversion of nutrients, metabolism of drugs and xenobiotics, protection against 
pathogens, and regulation of host immunity83–85. The interplay between the microbiota and 
the immune system is crucial for maintenance of regulatory pathways involved in the 
maintenance of intestinal homeostasis. Moreover, it has been hypothesized that change of 
lifestyle in developed countries, overuse of antibiotics, changes in diet, and a decrease in 
exposure to diverse microorganisms and parasites select a microbiota that lacks the 
resilience and diversity required for immune education and stimulation of immune-regulatory 
responses59. This might contribute to the uneven geographical distribution of inflammatory 
and autoimmune diseases in the world4. 
1.4.1 Microbial dysbiosis and IBD 
A decade of genome-wide association studies and genetic studies has highlighted the 
importance of the host–microbe interactions in the pathogenesis of IBD and proposed a link 
between the aberrant immune response in IBD patients to the intestinal microbiota. In the 
recent years, intestinal microbiome studies have associated compositional and functional 
shifts of the intestinal microbiome, also known as dysbiosis, to pathogenesis of many 
infectious and inflammatory diseases31,86. Dysbiosis can occur as a result of the loss of 
beneficial microorganisms, the expansion of potentially harmful microorganisms or 
pathobionts, or loss of overall diversity87. The same factors that influence the composition of 
the microbiota can contribute to the development of the dysbiosis, such as diet, enteric 
infections, use of medications, hygiene, physical activity, familial transmission, and 
genetics88.   
In general, an overall loss of microbial diversity, dysbiosis, and changes in microbiota 
metabolic output have been reported in IBD patients and are hypothesized to promote 
disease development89–91. The exact identity of specific bacterial members that can trigger 
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aberrant host responses and contribute to IBD development in humans is not exactly known 
since direct causal relationships between microbiota and IBD have been difficult to prove 
outside animal models. Nevertheless, several studies in humans described associations 
between IBD and increased abundance in Gammaproteobacteria and presence of 
Enterobacteriaceae, particularly adherent-invasive E. coli (AIEC) strains92.  Another study 
analyzed the microbiota of a large cohort of newly diagnosed, treatment-naive children with 
CD, and demonstrated an increased abundance of Enterobacteriaceae, Pasteurellaceae, 
Veillonellaceae, and Fusobacteriaceae in ileal and rectal biopsy samples93. In mouse 
models, additional members of the microbiota were identified to directly exacerbate 
intestinal inflammation or were found to be enriched in communities which promote disease 
severity. This includes members of the Enterobacteriaceae family, i.e. Klebsiella 
pneumoniae and Proteus mirabilis94,95, Akkermansia muciniphila96, distinct Bacteroides97 
and Helicobacter species98, as well as members of Prevotella genus18,99. Currently, it 
remains unknown whether dysbiosis of the gut microbiota is the cause of inflammation or a 
result of bacterial adaptation to the new intestinal environment caused by the inflammation. 
1.5 Intestinal commensals as immune modulators 
In the recent years progress has been made in understanding the interactions between the 
microbiota and the mucosal immune system. As the influence of the microbiota on 
regulation of immune functions becomes evident, characterizing the role of individual 
commensal bacteria became an area of scientific and clinical relevance. With the 
advancement of “next generation sequencing” (NGS) methods and utilization of gene-
deficient and gnotobiotic animal models, microbial communities and individual commensals 
have now been demonstrated to specifically modulate different aspects of host immunity. 
Remarkably, gut microbiota has a role beyond the local gut immune system and impacts 
many systemic immune components. For instance, modulation of immune responses may 
result in alteration of enteric infection susceptibility as well as development of autoimmune-
related diseases100,101. The following sections give a brief overview of several well-studied 
examples of specific members of the gut microbiota that have been linked with 
immunomodulatory properties. 
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1.5.1 Bacteroides fragilis 
Among the numerous Bacteroides species that have been reported to modulate host 
immune responses, B. fragilis is the most studied one. Interestingly, both anti- and pro-
inflammatory properties have been reported for distinct strains of B. fragilis. The first report 
showing a unique commensal molecule could promote regulatory responses was 
demonstrated by the identification of the polysaccharide A (PSA) produced by a B. 
fragilis strain102. Presence of polysaccharide A in B. fragilis is responsible for expansion of 
Tregs via TLR2 signaling in germ-free mice103. Induction of such immune-regulatory 
responses provides protection from chemically-induced colitis in animal models. 
Furthermore, PSA in B. fragilis was shown to promote IL-10 secretion in CD4+ cells, while 
suppressing Th17 pro-inflammatory response104. Another strain, enterotoxigenic B. fragilis 
(ETBF) has been linked with potent Th17 response and severe colitis105. 
1.3.2 Clostridium spp. 
Clostridia are a heterogeneous group of Gram-positive, spore-forming bacteria within the 
Firmicutes phylum including a large number of species of commensal bacteria and human 
pathogens, such as toxin-producing members Clostridium tetani, C. perfringens, and C. 
difficile. Commensal non-toxicogenic Clostridia have been implicated in the maintenance of 
mucosal homeostasis and prevention of IBD106. Induction of Treg cells is not restricted to B. 
fragilis as the presence of an indigenous Clostridium species also promotes Treg cell 
expansion by promoting TGF-β secretion107. Interestingly, induction of Tregs in the colon 
was increased when mice were colonized with a consortium of Clostridia spp., whereas 
individual species had a modest effect on the immune system108. Clusters IV and XIVa were 
demonstrated to play a significant role in maintaining intestinal function by producing 
butyrate109. Furthermore, independent studies reported these two Clostridia clusters to be 
reduced in IBD patients106,110. 
1.5.3 Faecalibacterium prausnitzii 
F. prausnitzii, a member of the Clostridia, is one of the most prevalent species in the human 
gut microbiota111,112. It has been associated with health benefits for the host due its 
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production of SCFA, mostly butyrate. Butyrate has been linked to anti-inflammatory effects 
as its presence modulates expansion of regulatory Tregs and secretion of IL-10 in dendritic 
cells113. Importantly, F. prausnitzii has been routinely found in lower relative abundances in 
UC patients compared to healthy individuals114,115. In animal models it has been further 
demonstrated that administration of F. prausnitzii leads to a significant decrease in 
inflammation severity116. Moreover, it has been demonstrated that F. prausnitzii ameliorates 
colorectal colitis by inhibition of IL-17 in rats117. Additional mechanisms of anti-inflammatory 
effects in F. prausnitzii have been reported, such as the inhibitory effect on NF-kB signaling 
in IECs in vitro110. 
1.5.4 Segmented filamentous bacteria (SFB)  
SFB are Gram-positive, spore-forming, filamentous bacteria reaching up to 80 µm in 
length118. Analysis of 16S rRNA sequence of mouse SFB revealed that the microbes belong 
to a novel genus in the order Clostridiales119. Although initially discovered in murine 
intestine118, there is now evidence that SFB-like bacteria exist in a broad range of species, 
including humans, non-human primates, chickens, horses, and other animals120,121. The first 
segment of the microbe possesses a nipple-like appendage that projects into the plasma 
membrane of the enterocyte, without actually rupturing or penetrating the host cell wall118. 
This close contact with IECs allows them to exert strong immunomodulatory properties. 
They are best known for their role in expansion of Th17 cell in small intestine which has 
been shown to provide protection in the large intestine against enteric Citrobacter rodentium 
infection122. However, recruitment of SFB-induced Th17 cells to systemic sites can have 
detrimental effects by promoting inflammatory disease, such as arthritis and multiple 
sclerosis123. SFB are also known to induce serum amyloid protein A (SAA), which via 
dendritic cells impacts the IL-22 production in innate lymphoid cells (ILCs)124. Even though 
SFB induce Th17 cells, they do not cause aberrant intestinal inflammation suggesting Th17 
cells induced by SFB may be qualitatively different from pathogenic Th17 induced during 
colitis or other inflammatory disorders125. 
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1.5.5 Helicobacter spp. 
Helicobacter spp. are Gram-negative, flagellated bacteria within the phylum of 
Proteobacteria. They are widely present in experimental mouse colonies around the world126 
as well as wild house mice127. Numerous species isolated from the intestine of mice are 
suspected to be pathobionts based on their ability to induce or enhance colitis in immune-
deficient mice, but not WT98,128,129. Specifically, H. hepaticus has been shown to promote 
intestinal inflammation in Rag2- and IL-10-deficient mice by activation of IL-17 and IFN-γ 
producing CD4+ T cells130. However, infection of WT mice results in the induction of IL-10-
producing Treg cells that prevented bacteria-induced colitis131. These findings suggested 
Helicobacter in the intestine induce regulatory T cells during homeostasis and effector T 
cells during colonic inflammation. Besides H. hepaticus, other species have been shown to 
modulate the immune response, including H. typhlonius and H. rodentium132.  
1.5.6 Escherichia coli 
E. coli are Gram-negative bacteria and belong to the family of Enterobacteriaceae that 
includes many commensals, opportunistic bacteria, and strict pathogens133. In the last 
decades, E. coli and in particular adherent-invasive E. coli (AIEC) has been implicated in the 
pathogenesis of IBD both in mouse models and IBD patients. AIEC ability to adhere and 
invade epithelial cells has been shown to trigger TNF-α production in macrophages. The 
ability of AIEC to adhere and invade epithelial cells triggers TNF-α production in 
macrophages. Additionally, non-AIEC E. coli have been reported to induce Th17 response 
in GF mice and have the ability to promote inflammation in genetically susceptible host134. 
Immuno-modulatory capability was shown as well in probiotic strain E. coli Nissle 1917, 
which promotes immune regulation by expansion of plasmacytoid DC and 
Foxp3+Rorgt+CD4+. 
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Figure 1: Multiple bacterial species and microbial metabolites modulate immune 
response in the intestine. 
Segmented filamentous bacteria (SFB) induce T helper (Th) 17 cells in the intestinal lamina propria 
via mechanisms that involve host production of serum amyloid A (SAA) or direct activation via antigen 
presenting cells (APC). Helicobacter species can induce effector T cells and promote inflammation in 
immuno-deficient host, whereas the Helicobacter-derived polysaccharides (PS) have been shown to 
interact with TLR2 receptor on macrophages (MΦ) promoting IL-10 production and expansion of 
regulatory T cells (Treg). A group of Clostridia species, taken together or individually, have been 
demonstrated to induce colonic Treg via production of short-chain fatty acids (SCFAs). Induction of 
Treg has as well been linked to polysaccharide A (PSA) in B. fragilis which interacts with TLR2 on 
APCs. Although associated to several inflammatory conditions, mechanism of immune modulation by 
Prevotella spp. has not been fully understood. 
1.5.7 Proteus mirabilis 
Other members of Enterobacteriaceae have been reported to play a causative role in 
intestinal inflammation. Colonization of TRUC (Tbet-/-Rag2-/-) mice with both P. mirabilis and 
K. pneumoniae induces colitis in specific pathogen free (SPF) mice, but not in GF animals, 
suggesting their colitogenic properties depend on the microbiota community, rather than the 
host genetics94. Intestinal inflammation in Proteus-colonized mice was been later 
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demonstrated to be mediated by bacterial hemolysin and its ability to induce NLRP3 
signaling in monocytes resulting in the production of mature IL-1β95. 
 
It is clear that the efforts of identifying individual members of the microbiota and their effects 
on the immune system are still in their infancy. However, scientists have started to transit 
from describing the association between microbial communities and diseases to 
investigating the immunomodulatory ability of specific microbes. Identification of 
immunomodulatory microbes and/or metabolic product may have great value in future 
development of therapeutics, including treatments for autoimmune disorders, inflammatory 
diseases, and enteric infections. 
 
1.6 Prevotella spp. in health and disease 
The genus Prevotella contains obligate anaerobic Gram-negative bacteria of the 
Bacteroidetes phylum. Some of the known Prevotella species have been reported to be 
involved in opportunistic infections, while most of them are classically considered to be 
commensal colonizing different mucosal sites – oral, intestinal, and vaginal135. Prevotella 
spp. were found to be a biomarker in one of the three human gut enterotypes112. Recent 
studies have associated the prevalence of Prevotella to non-Westerners and agrarian 
societies who consume a plant-rich diet136,137 as well as individuals with vegetarian dietary 
habits138. Moreover, it has been shown that Prevotella spp. can improve glucose 
metabolisms stimulated by the intake of prebiotics139. Together, these studies 
suggest Prevotella spp. have positive effects on the host and can be considered beneficial 
microbes.  
In contrast, other studies have associated Prevotella spp. with autoimmune diseases, insulin 
resistance and diabetes, and gut inflammation99,140,141. Specifically, an overabundance 
of Prevotella copri was noted in new-onset rheumatoid arthritis patients99. In mouse models, 
an altered gut microbiota dominated by a member of the genus Prevotella was discovered in 
NLRP6-deficient mice and was associated with higher susceptibility to chemically-induced 
colitis18. Interestingly, Prevotella spp. along with SFB and Helicobacter spp. are among the 
highest IgA-coated bacteria in these mice, which has been interpreted to reflect their 
immunogenic features69. Dysbiotic community derived from Nlrp6-/- mice (DysN6) affected 
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the severity of intestinal inflammation in an immunocompetent host via antigen-specific 
CD4+ T cells67. In addition, this community was characterized by an altered metabolic profile 
that can suppress inflammasome activation, and consequently reduce IL-18 maturation and 
antimicrobial peptide secretion46. Moreover, studies have shown that intestinal dysbiosis in 
HIV patient is characterized with increased abundance of Prevotella spp., which has been 
suggested to be the driver of persistent inflammation in the gut142. While some studies in 
IBD patients support the findings in mice143,144, other studies showed no associations91. 
These data suggest that a Prevotella-dominated microbiome may have the propensity to 
promote inflammation and intestinal dysbiosis, yet the direct functional relevance of 
increased Prevotella colonization is largely unclear. 
In summary, there are compelling associations in mice and humans that certain Prevotella 
species can promote inflammatory disease. However, there is a need for more mechanistic 
and causal studies to demonstrate a potential disease-triggering role for Prevotella spp. 
1.7 Microbiota-associated immunomodulatory metabolites  
The microbiota synthesizes and converts vast numbers of metabolites, however, current 
limitations in technical approaches limit our knowledge on the number and diversity of 
microbial metabolites. These include metabolites produced from dietary components, 
metabolites produced by the host and modified by the gut bacteria, and de novo synthesized 
compounds145.  It has become clear that the molecules produced through microbiota activity 
provide important signals to the host and have the ability to shape the immune system. 
However, observations connecting the microbiota, the metabolome and the immune 
response have been sporadic and only at the beginning of its discovery146. The following 
section discusses the most studied examples of metabolites shaping the gut-immune axis in 
the past decade. 
1.7.1 Short-chain fatty acids (SCFA) 
All animals, including humans, lack the enzymes to digest dietary fibers. These indigestible 
polysaccharides are fermented in the cecum and in the large intestine by members of 
intestinal microbiota. The major products of the fermentation process are the so-called short-
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chain fatty acids with acetic, propionic, and butyric acids being the most abundant147. The 
colon absorbs SCFAs across the apical membrane in the dissociated form mostly by an 
anion exchange process with bicarbonate. A small part of undissociated SCFAs may be 
transported via passive diffusion148.  
As an end product of microbial fermentation of dietary fiber, production of SCFAs in the 
intestine is firmly dependent on the diet and the microbiota composition. Members of 
Clostridia and Bacteroidetes have been reported to be main producers of SCFAs. While 
production of butyrate has been associated to Clostridia, members of the Bacteroidetes 
have been reported to be a major contributor to acetate production149,150. Therefore, the 
complex and delicate interaction within the microbiota may also control the proportion and 
levels of SCFAs in the gut lumen. 
Over the past few decades, it became evident that SCFAs have an impact on various 
aspects of the host physiology and play an important role in the maintenance of intestinal 
health. Apart from being a major energy source for colonocytes, SCFAs play a role in the 
prevention and treatment of the metabolic syndrome151,152, certain types of cancer153, and 
inflammatory bowel disorders 154–156. Even though positive anti-inflammatory effects in the 
treatment of ulcerative colitis and Crohn's disease have been demonstrated over twenty 
years ago, the molecular mechanism by which SCFAs modulate host immune response to 
promote homeostasis is still an active, ongoing field of research today. 
In the recent years, two major SCFAs signaling mechanisms have been identified; first, the 
activation of G-protein-coupled receptors (GPCRs) and second, the inhibition of histone 
deacetylases (HDACs, a class of regulatory proteins that function as inhibitors of gene 
expression). Several GPCRs, particularly GPR43, GPR41, and GPR109A, have been 
identified as receptors for SCFAs. Since they sense free fatty acids, GPR43 and GPR41 are 
also known as free fatty acid receptors (FFARs), FFAR2 and FFAR3, respectively. GPR43 
and GPR41 expression have been identified along the entire gastrointestinal tract and in a 
wide range of immune cells (basophils, neutrophils, monocyte, dendritic cells and mucosal 
mast cells) suggesting a broad role of SCFAs in immune signaling157,158. Probably the most 
potent anti-inflammatory property of SCFAs is their ability to promote Tregs. A study by 
Smith and colleagues demonstrated that GPR43 can also be expressed on intestinal Treg 
cells and that SCFAs stimulate their expansion and IL-10 production159. In contrast, another 
study reported that an effect of SCFAs on cytokine production in T cells is regulated via 
GPCR-independent mechanism, since the expression of GPR43 in Tregs is not 
significant160. Nevertheless, two independent studies showed that fiber-derived SCFAs 
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indeed promote the generation of Treg cells, but via inhibition of histone deacetylase 
(HDAC)161,162. Both studies showed a link between SCFAs and Treg cells as mice fed with 
high-fiber diet or only butyrate displayed an increase in the number of Treg. The increase in 
Tregs was related to the increased histone H3 acetylation within a genetic locus required for 
Treg induction, namely Foxp3161,162. In addition, SCFAs have been described to promote B 
cell differentiation into antibody-producing cells163. 
Expressing both receptors, GPR43 and GPR109a, intestinal innate immune cells and IECs 
are also affected by SCFAs. Acetate and butyrate can act on GPR43 and GPR109a 
receptors on IECs, respectively, and stimulate them to produce cytoprotective IL-1863,164,165. 
SCFAs-GPR43 signaling was reported to be important for neutrophil chemotaxis and 
resolution of intestinal inflammation in a model of chemically induced colitis158,166. GPR43-
deficient mice (GPR43-/-) showed exacerbated intestinal inflammation in comparison to wild-
type (WT) littermates. Feeding WT mice, but not GPR43-/-mice, with 200 mM acetate in their 
drinking water resulted in a substantial decrease of intestinal inflammation158.  
Interestingly, SCFA production in the intestine has been shown to have far-reaching 
consequences for the host, as SCFA have an impact on host physiology even in systemic 
sites. In rodent models, fermentation of dietary fiber and SCFA production have been 
causally linked to reduced weight gain and improved glucose tolerance151,152. A high-fiber 
diet (producing high amounts of acetate) suppresses allergic airway disease by enhancing 
regulatory immune responses167. Recent discoveries have suggested significant effects of 
SCFAs on peripheral as well as the central nervous system. For example, SCFAs impact the 
numbers and function of the microglia in the brain168, as well as regulate the permeability of 
the blood-brain barrier169. In addition, SCFAs have been identified as potent regulators of 
osteoclast metabolism and bone homeostasis170. A wide range of effects on host physiology 
and pathophysiology clearly makes the SCFAs and interesting candidate for development of 
new treatments for numerous diseases.  
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Figure 2: SCFA regulation of intestinal immunity.  
SCFA modulate the intestinal mucosal immunity through exerting their effects on various immune and 
epithelial cells, all expressing distinct G–coupled receptors (GPR). The differentiation of T cells is 
mediated both by the effects of SCFA on dendritic cells (DC) and the direct act of SCFA on naive T 
cells, both promoting regulatory immune responses – specifically the expansion of Tregs and IL-10 
production. SCFA induce neutrophils migration to an inflammatory site and enhance their 
phagocytosis. In addition, SCFA regulate intestinal barrier integrity by inducing intestinal epithelial cell 
secretion of IL-18 and upregulating the expression of the tight junctions (TJ). Effects of SCFA on IgA 
production in B cells have been as well reported.  
1.7.2 Polyamines 
Polyamines such as putrescine, spermidine, and spermine are derived from the precursor 
amino acids arginine and ornithine171. They are present in every living cell and play an 
important role in numerous biological processes, including gene expression, prokaryotic and 
eukaryotic cell proliferation, response to cellular stress, and metabolism172. The colonic 
lumen contains polyamines found in the diet or exported by enteric bacteria173. As germ-free 
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mice feature increased levels of arginine and diminished levels of polyamines, commensal 
bacteria have been suggested to play a part in the metabolism of arginine to downstream 
polyamines174. 
Despite the known role of polyamines in intestinal homeostasis, still not much is known 
mechanistically about their function. They have been associated with anti-inflammatory 
functions by acting on various cell types, including macrophages and epithelial cells175,176. 
Furthermore, an increase in polyamine levels in the intestine was shown to enhance the 
development of intestinal mucosa and recovery from injury177,178. They have been shown to 
exert protective effects against C. rodentium driven colitis179. In addition, polyamines play a 
role in the maintenance of intestinal barrier and permeability by altering the synthesis, 
expression, and stability of tight junction proteins180,181. 
Contrary to these observations, a recent report demonstrated that polyamines inhibit 
inflammasome signaling and IL-18 production46. Interestingly, another metabolite, taurine, 
was described to counteract the polyamine effects suggesting a fine balance of microbial 
metabolites play an important role in shaping the immune system46.  
1.9 Experimental models of IBD  
CD and UC are complex diseases that originate from an overt immune response to enteric 
microbiota in the genetically susceptible host182. A number of mouse models have been 
developed to investigate the pathogenesis of IBD and discover targets for treatments. Over 
the past two decades, they have provided important insights into the immunopathogenesis 
responsible for the development of intestinal inflammation183. Even though no single model 
captures the complexity of immunopathology of CD and UC, they offer distinct advantages 
and provide valuable insights into one or more aspects of IBD.  
Currently, there are over 50 mouse models of intestinal inflammation183 and can be grouped 
into 4 broad categories that include genetically engineered, spontaneous, immune-
manipulated, and chemically-induced colitis184,185. Some of the most widely and commonly 
used colitis models include T cells transfer colitis, genetically engineered TNF-α 
overexpressing (TnfΔARE model)186 and IL-10 deficient mice models187, as well as chemically 
induced dextran sodium sulfate (DSS)188 and 2,4,6-trinitrobenzene sulfonic acid (TNBS) 
colitis189. Since the DSS colitis model was used throughout the experimental part of this 
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thesis to study intestinal tissue damage and inflammation, its characteristics and 
advantages are summarized in the following section. 
1.9.1 Dextran sulfate sodium (DSS) colitis 
DSS is a sulfated polysaccharide that is directly toxic to the colonic epithelium. 
Administration of DSS for short periods of time in the drinking water of mice causes injury to 
the intestine and results in acute inflammation190. Inflammation is predominantly limited to 
the colon and it is characterized by general disruption of the epithelial barrier, including 
epithelial erosion, loss of crypts, and infiltration of granulocytes191. Clinically, diarrhea, 
bloody stool, weight loss, and eventually death are observed in mice treated with DSS188,191. 
As intestinal inflammation is induced independently of adaptive immune cells (SCID and 
Rag2-/- mice)192, DSS model has been useful in studying innate immune pathways in colitis 
induction. As the major feature of DSS colitis is disruption of the intestinal barrier, it is a 
useful model for studying maintenance of the epithelial integrity and tissue repair after 
injury190. 
Advantages of this model are simplicity, low cost, reproducibility, rapid onset of inflammation 
and histopathological similarity to ulcerative colitis183. A search in PubMed (June 2018) 
reveals that over 3000 studies published have used DSS colitis model, making it the most 
frequently used model. 
 
Despite the success of advancing our understanding of IBD immunopathology, largely 
attained from numerous studies in animal models, there has been a significant challenge to 
translate the preclinical research into successful treatments. The rate of translation of 
efficacious treatment strategies is relatively low, from 60 new therapeutic targets that have 
been evaluated in over 600 phase I-III clinical studies, only 4 of them have been approved 
for patient treatment193. It has been suggested that the low success rate of generating new 
treatments for IBD is not only due to limitations of animal models, but mostly due to 
numerous and diverse genetic predisposing factors and complexity of interactions with the 
various gut microbiota in IBD. As discussed, IBD constitute very heterogeneous conditions 
and distinct phenotypes, and as such personalized approach to each patient may allow 
greater success in treatment194.  
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1.10 Aims of the work 
The microbiota affects hosts physiology largely by shaping the development of the immune 
system, the type of immune responses, the metabolism, and by directly preventing the 
colonization of invading pathogens. Technical advances of culture-independent methods 
have allowed the extensive characterization of microbial communities in humans and animal 
models and have established associations between alteration in microbiota composition and 
a wide range of metabolic disorders, autoimmune and infectious diseases. Regardless of 
this progress, moving from observational to mechanistic studies and demonstrating cause-
effect relationships remains a major challenge in performing these studies as isolation and 
culture of members of intestinal microbiota is still a critical step. 
Recent studies in humans and animal models have associated increased relative 
abundance of members of Prevotellaceae family within diverse microbial ecosystems with a 
wide range of inflammatory diseases. Yet, whether these species actively propagate 
inflammation in these ecosystems remains unknown. Particularly, the role of members of the 
Prevotella genus within the intestinal microbiota and their effects on intestinal homeostasis 
and inflammation is not completely understood. The detailed investigation of the 
immunomodulatory properties of Prevotella spp. and their potential mechanisms have been 
restricted by the poor characterization of intestinal Prevotella species as well as the lack of 
diverse intestinal Prevotella isolates. As of now, culture collections include three Prevotella 
isolates from the human intestine, while no species isolated from mice are available.  
Altogether, these findings bring into a question whether Prevotella species are indeed linked 
to inflammatory disorders or rather a bystander in these microbial communities. Hence, the 
aim of the present work was to investigate whether presence of Prevotella in the intestine 
promotes inflammatory diseases, in particular intestinal inflammation. Since performance of 
detailed studies has been  hampered by limited availability of intestinal isolates, not only 
human but from model organisms such as the mouse, the aim of the present work was to 
isolate distinct species of the Prevotella genus from gut microbial communities in mice prone 
to intestinal inflammation using a step-wise enrichment and targeted isolation. The mouse 
isolate with the highest genetic similarity to known human intestinal isolates was selected 
and used as a representative species for investigating the role of Prevotella spp. in the 
intestine. Using wild-type (WT) mice with a defined specific pathogen free (SPF) microbiota 
composition, and devoid of any Prevotella species, we aimed to study the impact of the P. 
intestinalis colonization on the composition and function of the resident microbiota. 
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Furthermore, the aim of the work was to functionally study the consequence of P. intestinalis 
colonization on the intestinal homeostasis and inflammation using an animal model of 
chemically induced tissue injury. Investigation of immunomodulatory potential of P. 
intestinalis was performed by global analysis of infiltrating immune cells and cytokine 
production as well as by using immune-deficient mice models. Members of the intestinal 
microbiota have been shown to modulate the immune response directly or via production of 
immuno-modulating metabolites. Whether Prevotella immunomodulation capacity comes 
from its immunogenic properties and/or metabolic activity was evaluated using in vitro cell 
culture assays and targeted metabolome analysis.  
Together this comprehensive investigation advanced our understanding of the impact of 
Prevotella spp. on the intestinal ecosystem and the modulation of intestinal homeostasis 
and inflammation. 
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Materials 
 
2.1 Experimental mouse models 
Wild-type and all transgenic mice, Rag2-/- and IL-17AGFP IFN-γKatushka FoxP3RFP reporter mice 
used in the study were on the C57BL/6N background. They were all bred and maintained at 
the animal facilities of the Helmholtz Centre for Infection Research (HZI) under enhanced 
specific pathogen-free conditions (SPF). All transgenic mice were rederived into SPF 
microbiota by embryo transfer37. Nlrp6-/- mice were obtained from Yale University and 
subsequently bred under conventional housing conditions at the HZI without rederivation. 
Other used WT mice with different microbiota were purchased either from Janvier Labs 
(barrier 10C) or were obtained from National Cancer Institute (NCI) and bred under 
conventional housing conditions at the HZI without rederivation. Germ-free WT mice were 
bred in isolators (Getinge) in the germ-free facility of the HZI. All experiments were carried 
out with gender- and age-matched animals.  
All mice were provided with sterilized food and water ad libitum. Mice were kept under strict 
12 h light cycle and housed in individually ventilated cages (IVC) in groups of up to 5 mice 
per cage. During the experiment, all mice were kept in airtight ISOcages, containing HEPA-
filter, to prevent contamination. All animal experiments have been performed with the 
permission of the local government of Lower Saxony, Germany. 
Materials 
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2.2 Bacterial strains 
Table 1 Bacterial cultures used in this study 
Bacteria Source 
Prevotella intestinalis Laboratory stock; Isolated from colonic content of 
Nlrp6-/- mice 
Prevotella rodentium Laboratory stock; Isolated from colonic content of 
WT mice (Janvier Labs, barrier 10C) 
Prevotella muris Laboratory stock; Isolated from total intestinal 
content of WT mice (NCI) 
Bacteroidetes acidifaciens DSMZ 100502 
2.3 Reagents 
2.3.1 Oligonucleotides and probes 
Table 2 PCR and qPCR primers used in this study 
Oligonucleotide Sequence 
16S_V4Seq 
515F:5´AATGATACGGCGACCACCGAGATCTACACT
ATGGTAATTGTGTGCCAGCMGCCGCGGTAA 
806R: 5´GGACTACHVGGGTWTCTAAT 
16S_SangerSeq 
27F: 5´AGAGTTTGATCMTGGCTCAG 
1492R: 5´TACGGYTACCTTGTTACGACTT 
16S_qPCR 
334F: 5´ACTCCTACGGGAGGCAGCAGT 
514R: 5´ATTACCGCGGCTGCTGGC 
P_intestinalis 
181F: 5´CGTCCCTTGACGGCATCCGACA 
1032R: 5´CAGCCCCGAAGGGAAGGGGTG 
P_rodentium 
603F: 5´TGAAATGTCGGGGCTCAACCTTGACAC 
1289R: 5´GCGGCTTTACGGATTGGACGTACG 
P_muris 
61F: 5´GGCAGCATGACATGTTTTCGGACGT 
642R: 5´CAGTTCGCGCTGCAGGACCG 
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Table 3 Primer probes used to quantify relative gene expression in this study  
Oligonucleotide Sequence 
Il18 Applied Biosystems (Mm00434225_m1) 
Casp1 Applied Biosystems (Mm00438023_m1) 
Nlrp6 Applied Biosystems (MM00460229_m1) 
Ang4 Applied Biosystems (Mm_03647554_g1) 
Retnlb Applied Biosystems (Mm_00445845_m1) 
Reg3g Applied Biosystems (Mm_0044127_m1) 
Hprt 
F: CTGGTGAAAAGGACCTCTCG; 
R: TGAAGTACTCATTATAGTCAAGGGCA; 
Probe:TGTTGGATACAGGCCAGACTTTGTTGGAT 
 
2.3.2 Antibodies 
Table 4 Antibodies used in this study 
Antibody Clone Source 
anti-CD45 30-F11 Biolegend 
anti-CD3 17A2 Biolegend 
anti-CD4 RM4-5, GK1.5 Biolegend 
anti-CD8a 53-6.7 Biolegend 
anti-CD44 IM7 Biolegend 
anti-CD62L MEL-14 Biolegend 
anti-IL-17A TC11-18H10.1 Biolegend 
anti-IFNγ XMG1.2 Biolegend 
anti-MHC class II M5/114.15.2 Biolegend 
anti-CD11b M1/70 Biolegend 
anti-CD11c  N418 Biolegend 
anti-Ly6G IA8 Biolegend 
anti-Ly6C HK1.4 Biolegend 
AlexaFluor350 NHS Ester N/A Life Technologies 
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2.3.3 Chemicals, Peptides and Recombinant Proteins 
Table 5 Chemicals, peptides, and recombinant proteins used in this study 
Reagent Source 
ALBUMIN BOVINE, FRACTION V MP Biomedicals 
Avidin-HRP BioLegend 
Bacto Agar BD Bioscience 
Brain Heart Infusion Broth BHI Oxoid 
Chloroform 
Avantor Performance 
Materials 
Collagenase D Roche 
cOmplete Protease Inhibitor Cocktail Tablets Roche Diagnostics 
DEXTRAN SULFATE SODIUM SALT (36000-50000 
M.Wt.) Colitis Grade 
MP Biomedicals 
Dispase Corning 
DNase I Roche 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma-Aldrich 
Dulbecco’s Phosphate Buffered Saline (without 
CaCl2, MgCl2) 
Sigma-Aldrich 
Dulbecco’s Phosphate Buffered Saline (with CaCl2, 
MgCl2) 
Sigma-Aldrich 
Ethanol 
Avantor Performance 
Materials 
Ethylenediamine tetraacetic acid disodium salt 
dihydrate (EDTA) 
Carl Roth 
Fetal Bovine Serum Sigma-Aldrich 
Glycerol Carl Roth 
Glycine Carl Roth 
L-Glutamine Thermo Fisher Scientific 
Hank´s Balanced Salt Solution (HBSS) Gibco 
Horse serum Sigma-Aldrich 
IGEPAL CA-630 Sigma-Aldrich 
Ionomycin Sigma-Aldrich 
IsoFlo Ecuphar 
Magnesium chloride MgCl2 Carl Roth 
Menadione crystalline Sigma-Aldrich 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich 
Penicillin-Streptomycin Solution Thermo Fisher Scientific 
Percoll GE Healthcare 
Polymerase Q5 High-Fidelity NEB 
Polymerase TSG BioBasic 
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Table 5 continued 
Reagent Source 
2-Propanol 
Avantor Performance 
Materials 
RNase AppliChem 
Recombinant Mouse IL-18 MBL 
RevertAid Reverse Transcriptase Thermo Fisher Scientific 
Roth poly d(T)12-18 Primer Carl Roth 
Roti-Phenol/Chloroform/Isoamyl alcohol Carl Roth 
Sheep blood (defibrinated) Thermo Fisher Scientific 
Sodium Acetate solution (3 M, pH 5.2) Panreac AppliChem 
Sodium carbonate Na2CO3 Carl Roth 
Sodium chloride NaCl Carl Roth 
Sodium Dodecylsulfate solution 20% pure Panreac AppliChem 
Sulfuric acid Carl Roth 
TE buffer (1X) pH 8.0 Panreac AppliChem 
Thioglycollate Medium BD Bioscience 
TMB Substrate Set BioLegend 
TRI Reagent Zymo Research 
TRIS Carl Roth 
Triton X 100 Carl Roth 
TWEEN 20 Sigma-Aldrich 
TWEEN 80 Sigma-Aldrich 
2.3.4 Commercial assays 
Table 6 Commercial assays used in this study 
Commercial Kits Source 
ELISA MAX Standard SET Mouse IL-6  BioLegend  
KAPA PROBE FAST qPCR Kit Kapa Biosystems 
KAPA SYBR FAST qPCR Kit Kapa Biosystems 
LEGENDplex Mouse Inflammation Panel Biolegend 
LEGENDplex Mouse Proinflammatory Chemokine 
Panel 
Biolegend 
Mix2Seq kit Eurofins Genomics 
Spin Column PCR Product Purification Kit BioBasic 
Materials 
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2.4 Buffers, Mediums and Agars recipes 
 
BHI-S+ (Brain Hearth Infusion Broth + supplements) 
 
Component Stock Volume/Mass Final concentration 
BHI n/a 9.25 g n/a 
Add 225 mL MilliQ water and autoclave for 12 min at 121oC 
FBS n/a 25 ml 10% (w/v) 
Menadione (vit K) 0.5 g/l 250 µl 0.5 mg/l 
Filter sterilize into the autoclaved BHI broth, keep away from light, reduce in 
anaerobic chamber for 2 days before use 
 
 
BHI-SVanc+ (BHI-S+ Vancomycin) 
 
Component Stock Volume/Mass Final concentration 
BHI n/a 9.25 g n/a 
Add up to 225 mL with MilliQ water and autoclave for 12 min at 121oC 
FBS n/a 25 ml 10% (w/v) 
Menadione (vit K) 0.5 g/l 250 µl 0.5 mg/l 
Vancomycin 7 mg/ml 250 µl 7 µg/ml 
Filter sterilize into the autoclaved BHI broth, keep away from light, reduce in 
anaerobic chamber for 2 days before use 
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BHI-SVanc+ agar plates 
 
Component Stock Volume/Mass Final concentration 
BHI n/a 18.5 g n/a 
Add 225 mL with MilliQ water and autoclave for 12 min at 121oC 
Bacto agar n/a 9 g n/a 
Add 250 mL with MilliQ water and autoclave 
Sheep blood n/a 25 ml 5 % (w/v) 
Menadione (vit K) 0.5 g/l 250 µl 0.5 mg/l 
Vancomycin 7 mg/ml 250 µl 7 µg/ml 
Add sterile supplements into the autoclaved BHI broth (RT), add together to 
autoclaved agar (40-50oC), pour 25 ml per petri dish, keep away from light, reduce in 
anaerobic chamber for 2 days before use 
 
Buffer A 
 
Component Stock Volume/Mass Final concentration 
NaCl n/a 1.16 g 200 mM 
Tris n/a 2.42 g 200 mM 
EDTA- DiNa n/a 0.74 g 20 mM 
Add 100 mL with MilliQ water and set pH to 8 
 
Hot shot Lysis Buffer 
 
Component Stock Volume/Mass Final concentration 
NaOH 10 N 62.5 µl 25 mM 
EDTA 0.5 M 10 µl 0.2 mM 
Add 25 mL with MilliQ water, pH=12 
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Neutralization Buffer 
 
Component Stock Volume/Mass Final concentration 
Tris-HCl 1 M 1 ml 40 mM 
H20 n/a 24 ml n/a 
pH=5 
 
ELISA Coating Buffer 
 
Component Stock Volume/Mass Final concentration 
NaHCO3 n/a 8.4 g 100 mM 
Na2CO3 n/a 3.56 g 34 mM 
Add 1000 mL MilliQ water and set pH to 9.5 
 
ELISA Washing Buffer 
 
Component Stock Volume/Mass Final concentration 
PBS n/a 1000 ml n/a 
Tween 20 n/a 500 μl 0.05% (w/v) 
 
 
ELISA Blocking Buffer 
 
Component Stock Volume/Mass Final concentration 
PBS n/a 100 ml n/a 
BSA n/a 1 g 1% (w/v) 
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Elution Buffer (EB) 
 
Component Stock Volume/Mass Final concentration 
Tris-HCl 1 M 0.5 ml 10 mM 
H2O n/a 45.5 ml n/a 
 pH=8.5 
 
NP-40 Lysis buffer 
 
Component Stock Volume/Mass Final concentration 
NaCl n/a 1.753 g 150 mM 
Tris- HCl (pH 8) 500 mM 20 ml 50 mM 
IGEPAL n/a 2 ml 1% (w/v) 
Add up to 200 mL with MilliQ water, before use add 1 tablet of protease inhibitors 
(Complete) per 50 mL buffer 
 
Fluorescence-activated cell sorting (FACS) Buffer 
 
Component Stock Volume/Mass Final concentration 
PBS n/a 100 ml n/a 
FBS n/a 1 ml 1% (w/v) 
 
DMEM Complete Medium 
 
Component Stock Volume/Mass Final concentration 
DMEM n/a 445 ml n/a 
FBS n/a 50 ml 10% (w/v) 
L-glutamin 200 mM 5 ml 2 mM 
Filter sterilize, store at 4oC 
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Bone Marrow-derived Macrophages Medium 
 
Component Stock Volume/Mass Final concentration 
DMEM n/a 315 ml n/a 
FBS n/a 50 ml 10% (w/v) 
L-glutamine 200 mM 5 ml 2 mM 
Penicillin (10,000U/ml) - 
Streptomycin (10,000 
µg/ml) 
- 5 ml 1% (w/v) 
Horse serum n/a 25 ml 5% (w/v) 
L292 supernatant n/a 100 ml 20% (w/v) 
Filter sterilize, store at 4oC 
2.5 Equipment 
Table 7 Appliances used in this study  
Equipment Source 
Anaerobic chamber  Coy Laboratory 
BD LSR  BD Biosciences 
BioPhotometer Plus Eppendorf 
Centrifuge 5430 R Eppendorf 
FlexCycler² Thermocycler Analytik Jena 
HERAcell 150i CO2 incubator Thermo Fisher Scientific 
Light Cycler 480 Instrument Roche Diagnostics 
Mainz COLOVIEW System Karl Storz 
Microscope Eclipse TS100 Nikon 
Mini-Beadbeater-96 Bio Spec 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific 
peqTWIST Vortex VWR 
Savant DNA SpeedVac Thermo Fisher Scientific 
Synergy 2 Multi-Mode Reader Biotek 
Thermo Mixer comfort Eppendorf 
Materials 
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2.6 Software and Algorithms 
Table 8 Software and Algorithms used for data analysis in this study 
Software and Algorithms 
FlowJo software  
GraphPad Prism v 6.0 
R statistical programming environment; R version 3.3.0 (2016-05-03) 
Quantitative Insights into Microbial Ecology (QIIME) v 1.8.0  
Silva Ref NR database Version 123.1 
Greengenes reference database 
Ribosomal Database Project (RDP) classifier  
OTU picking with UCLUST 
FastTree Price  
Phyloseq 
LEfSe 
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Methods 
 
3.1 Anaerobic isolation of novel Prevotella spp.  
Before the start, all materials and reagents were reduced to anaerobic conditions by placing 
them in anaerobic chamber for a minimum of 48h. The fresh colonic content of 
conventionally housed donor Nlrp6-/- mice was collected in BBL thioglycollate media, 
weighted and homogenized by vortexing. The fecal content homogenate was further 
processed in an anaerobic chamber with following gas mixture: 70% nitrogen, 20% carbon 
dioxide and 10% hydrogen. To remove undigested foods and other bigger particles, the 
content was filtered through 70 μm sterile filter and diluted to a concentration of 40 mg/ml. 
Bacteria were isolated by using the most probable number (MPN) technique195 where 
homogenized content was diluted in a range in which maximal 30% of wells showed 
detectable growth. Specifically, 10-fold dilutions (10-6 and 10-7) of fecal content homogenate 
were cultured in a sterile 96-well plate in Brain Hearth Infusion broth (BHI), supplemented 
with 10% FBS and 0.5 g/l vitamin K (BHI-S+) on 37 oC for 2 days. To identify Prevotella-
positive wells, DNA of all 96 wells was isolated via hot shot lysis and screened for Prevotella 
spp. growth by PCR using specie-specific primers. Prevotella-positive wells were further 
subcultured in 5 ml BHI-S+ medium containing vancomycin (BHI-SVanc+) to reduce the 
contamination of other bacteria and enrich for Prevotella spp. Prevotella-enriched cultures 
were further plated on BHI-SVanc-blood agar and single colonies were screened by PCR, 
using both Prevotella-specific primers and sequencing 16S rRNA gene amplicons. Positive 
colonies were passaged 3 times on agar plates before a pure culture was obtained and 
glycerol stocks were frozen in -80 oC. 
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3.1.1 Hot shot lysis 
To identify the isolated bacteria, DNA was isolated via Hot shot lysis. A 4 μl aliquot from 
each well culture was added to 40 µl of Hot shot lysis buffer and heated for 45-60 min on 95 
oC followed by the addition of 40 μl of Neutralization buffer. The neutralized lysate was 
further diluted 1:10 in Elution buffer (EB buffer) to reduce the amplification of background 
DNA present from dead or lysed cells. 
3.1.2 Prevotella spp. specific polymerase chain reaction (PCR) 
Isolated DNA from anaerobic bacterial cultures was tested for Prevotella growth using 
specific PCR primer pair (180F, 1032R) in the following PCR mixture: 
Component Volume (µL) Final concentration 
PCR buffer (10x) 5 1x 
MgSO4 (10x) 5 1x 
dNTPs 1 200 µM 
Forward Primer 1 200 µM 
Reverse Primer 1 200 µM 
Taq Polymerase 0.2 1U/ 50 µl 
Water  35.8 N/A 
DNA template 1 5 ng/µl 
 
PCR conditions were as follows:  
 
Cycle Step Temperature (oC) Time (s) # of cycles 
Initial denaturation 94 120 1 
Denaturation 94 20 
30 Annealing 60 20 
Extension 72 60 
Final extension 72 300 1 
Methods 
 
 
38 
 
3.1.3 16S rRNA gene amplification and Sanger sequencing 
Bacteria colonies grown on agar plates were identified by Sanger sequencing. Multiple 
colonies were picked with sterile inoculation loops directly in Hot shot lysis buffer. Isolated 
DNA served as a template for 16S rRNA amplification in a PCR reaction using specific 
primers (16S_27F, 16S_1492R) and following PCR conditions: 
 
Step Temperature (oC) Time (s) # of cycles 
Initial denaturation 94 120 1 
Denaturation 94 20 
11 Annealing 61 20 
Extension 72 60 
Denaturation 94 20 
26 Annealing 55 20 
Extension 72 60 
Final extension 72 300 1 
 
16S rRNA amplicons were purified using Spin Column PCR Product Purification Kit 
according to the manufacturer’s instructions and subsequently sequenced by Eurofins 
Genomics using Mix2Seq kit. 
3.2 Microbiota manipulation 
3.2.1 Prevotella intestinalis mice colonization 
For every experiment, fresh P. intestinalis culture was grown anaerobically (70% N2, 20% 
CO2 and 10% H2) from a frozen glycerol stock in BHI-S+ medium on 37 
oC for 2-3 days. All 
mice (unless indicated differently) were colonized at age of 4-5 weeks with 200 µl of freshly 
grown P. intestinalis culture (OD600=0,25) via oral gavage. 
Methods 
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3.2.2 Prevotella spp. competition 
Three Prevotella species, Prevotella intestinalis, Prevotella rodentium, and Prevotella muris, 
were grown anaerobically in BHI-S+ medium on 37 oC. All three cultures were grown to an 
OD600=0.25, mixed in 1:1:1 ration and co-transferred together by oral gavage in mice 
recipients. Before and after colonization feces samples were collected on different days and 
Prevotella spp. colonization kinetics was examined by quantitative PCR and 16 rRNA 
sequencing. 
3.3 Fecal bacteria DNA isolation 
Fresh stool samples or intestinal content were collected from mice and immediately stored 
at -20 oC. For DNA based 16S rRNA gene sequencing, DNA was extracted according to 
established protocols using a method combining mechanical disruption (bead-beating) and 
phenol/chloroform based purification (Turnbaugh et al., 2009). Briefly, samples were 
suspended in a solution containing 500 µl of DNA extraction buffer, 200 µl of 20% SDS, 500 
µl of phenol:chloroform:isoamyl alcohol (24:24:1) and 100 µl of 0.1 mm diameter 
zirconia/silica beads. Samples were then homogenized twice mechanically using Mini-
Beadbeater-96 for 2 min. After centrifugation (8,000 rpm for 5 min at 4 °C) of homogenized 
feces/fecal content, the aqueous phase was transferred to a new 1.5 ml tube and extraction 
was repeated by adding 600 µl of phenol/chloroform/isoamyl alcohol and centrifuging at 
12,700 rpm for 5 min at 4 °C.  Upper aqueous phase containing DNA was transferred into a 
fresh tube and further precipitated in 600 µl ice-cold 2-propanol with 60 µl of 3M sodium 
acetate solution at -20 °C for a minimum of 1h. To yield a DNA pellet, samples were 
centrifuged at 12,700 rpm for 20 min at 4 °C and subsequently washed in 1 ml of 70% 
ethanol. Finally, the crude DNA pellets were dried in a vacuum centrifuge for 10 min and 
resuspended in 200 μl of 1xTE buffer. Dissolved DNA samples were treated with 100 mg/ml 
RNase and column purified to remove PCR inhibitors. The isolated fecal microbial DNA was 
stored at -20 °C until further analysis. 
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3.3.1 DNA isolation from mucosa-associated bacteria 
Collected colons were opened longitudinally and content was removed by washing two 
times in sterile 1xPBS, or until all visible content was removed. Mucus associated bacteria 
were detached from the intestinal wall in three 1-min washes in 12.5 ml 0.1% (w/w) Tween 
80 in 1xPBS by vigorously shaking the tube. The washes were pooled and then centrifuged 
at 4,700 rpm, for 20 min at 4 °C to pellet the cells. The bacterial pellet was further 
resuspended in DNA extraction buffer (500 µl Buffer A and 200 µl of 20% SDS) and DNA 
was isolated using standard fecal bacterial DNA isolation protocol. 
3.4 16S rRNA microbial community sequencing 
Sequencing of fecal DNA was performed in the Genome Analytics Platform at Helmholtz 
Center for Infection Research. 
Amplification of the V4 region (F515/R806) of the 16S rRNA gene was performed as 
previously described protocols196. Samples were sequenced on an Illumina MiSeq platform 
(PE250). Barcode-based demultiplexing was performed using IDEMP software with default 
parameters (https://github.com/yhwu/idemp). Obtained reads were assembled, quality 
controlled and clustered using Usearch8.1 software package 
(http://www.drive5.com/usearch/). Briefly, reads were merged using -fastq_mergepairs –with 
fastq_maxdiffs 30 and quality filtering was done with fastq_filter (-fastq_maxee 1), minimum 
read length 200 bp. The OTU clusters and representative sequences were determined using 
the UPARSE algorithm197, followed by taxonomy assignment using the Silva database 
v128198  and the RDP Classifier199 with a bootstrap confidence cutoff of 80% performed by 
using QIIME v1.8.0200. OTU absolute abundance table and mapping file were used for 
statistical analyses and data visualization in the R statistical programming environment 
package phyloseq201. To determine bacterial OTUs that explained differences between 
microbiota settings, the LEfSe method was used202. OTUs with Kruskal-Wallis test < 0.05 
and LDA scores > 4.0 were considered informative. 
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3.5 Induction of acute DSS colitis 
Acute colitis was induced by adding Dextran Sodium Sulfate (DSS) in sterilized drinking 
water of 10-11 weeks old WT and gene-deficient mice. Mice were given 2.1% (w/v) DSS in 
drinking water for 7 days, followed by 5 days of access to regular drinking water. During the 
course of DSS treatment fresh DSS solution was prepared and replaced on day 0 and day 
4. Mice were monitored daily by measurement of body weight and clinical assessment, 
including stool consistency and detection of blood in the stool. Animals which lost 20% or 
more of their initial body weight were euthanized by carbon dioxide asphyxiation and/or 
cervical dislocation. 
3.6 Sacrifice and dissection of mice 
All procedures were performed according to the animal protection act and animal suffering 
was kept to an absolute minimum. Experimental samples were collected either in steady 
state (day 0) or during inflammation (day 7 of DSS treatment). Mice were euthanized by CO2 
inhalation, and death of the animals was confirmed by controlling the corneal and interdigital 
reflexes. For different analysis, colon, colon fecal content, cecum, cecum fecal content, 
small intestine, small intestine fecal content, and/or mesenteric lymph nodes were collected.  
3.6.1 Colon tissue sampling 
Colons were removed by making cuts at the proximal part connecting to the cecum and at 
the rectal part. Excised colons were divided into distal and proximal colon. Three 
centimeters of each part was cut open longitudinally, gently washed in 1xPBS to remove the 
fecal content, and further divided longitudinally into two samples for further processing - 
tissue homogenates (protein) preparation and RNA isolation. 
 
Methods 
 
 
42 
 
3.7 Tissue homogenates preparation 
One half of proximal and distal colon was collected in 1 ml NP-40 lysis buffer with protease 
inhibitors and 1.0 mm diameter zirconium/glass beads and always kept on ice. Tissue 
weight was recorded and samples were further mechanically homogenized using Mini-
Beadbeater-96 (Biospec). Protein extracts were centrifuged at 10,000 rpm for 5 min at 4 °C 
and the supernatants were stored at -80 °C until further analysis. 
3.8 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays (ELISA) were performed to determine concentration 
of different pro-inflammatory cytokines (IL-6 and IL-18) in colonic tissue and in supernatants 
of stimulated bone marrow derived macrophages (BMDM). The protocols for all measured 
cytokines were identical and were carried out according to the manufacturer´s instructions. 
One day prior to the assay flat-bottom 96-well plates were coated with 25 μL of capture 
antibody diluted in 1x Coating buffer and incubated overnight at 4 °C. The following day 
plates were washed 3 times with 120 μL Washing buffer and blocked for 1 h on RT with 50 
μL of Assay diluent to avoid unspecific binding Diluent. After washing, 25 μL of each sample 
and standard dilutions were prepared as stated by the manufacturer in the respective 
sample buffer or cell medium, which also served as a negative control. Twenty five μL of 
each sample (diluted if needed) and standard 2-fold dilutions were added to respective wells 
and incubated for 2 h on RT. All standards, negative controls and samples were done in 
duplicates. After the incubation, the plates were washed 3 times with 120 μL Washing buffer 
and 25 μL detection antibody diluted in Assay diluent was added to each well. After 1h 
incubation at RT, the plates were washed 3 times and 25 μL of avidin-conjugated horse 
radish peroxidase antibody (HRP) was added to each well. After 30 min incubation at RT the 
plates were washed 5 times with 120 μL of Washing Buffer. Subsequently TMB substrate 
solution was prepared by mixing the provided solutions A and B in a 1:1 ratio, and 25 μL 
was added to each well. Samples were kept in the dark until the desired color has 
developed. Reaction was stopped by adding 25 μL of 2N H2SO4. The absorbance was 
measured using ELISA plate reader - Synergy 2 analyzer on two wavelengths - 450 nm and 
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570 nm. The standard values were used to generate a linear standard curve based on which 
the sample concentrations were calculated. 
3.9 LEGENDplex immunoassay  
LEGENDplex immunoassay was performed to measure distinct cytokines and chemokines, 
either in intestinal tissue homogenates or cell culture supernatants.  According to the 
manufacturer´s instructions, samples were incubated in polypropylene microfuge tubes with 
different size beads set conjugated with distinct capture antibodies, together with assay 
buffer and a biotinylated detection antibody cocktail. Sample tubes were covered with 
aluminum foil to protect from light, and were shaken for 2 h on RT. After washing, 
Streptavidin-phycoerythrin (SA-PE) was added and incubated on RT for additional 30 min 
while shaking. Finally, the samples were washed, centrifuged at 1,800 rpm for 10 min, and 
resuspended in FACS buffer. The samples were then acquired on flow cytometer and 
different cytokine were differentiated by size and internal fluorescence intensity. The 
concentration of a particular cytokine was determined using a standard curve generated in 
the same assay. 
3.10 Total RNA isolation 
One half of proximal and distal colon was sampled and collected in 1 ml TRI reagent 
containing 1.0 mm diameter zirconium/glass beads and always kept on ice. After 
mechanical homogenization using Mini-Beadbeater-96, samples were incubated for 5 min at 
RT to permit the complete dissociation of nucleoprotein complexes. Next, samples were 
centrifuged at 300 g for 3min at 4 °C and the supernatant was transferred to a new 
Eppendorf tube prefilled with 200 μL of chloroform. The mixture was shaken vigorously by 
vortexing for 15 s and incubated at RT for 3 min. Samples were further centrifuged at 12,000 
g for 15 min for phase separation. The upper aqueous phase containing RNA was 
subsequently transferred into a fresh Eppendorf tube and 500 μL of 2-propanol was added 
for RNA precipitation. The mixture was vortexed and incubated overnight at -20 °C. The next 
day samples were centrifuged at 12,000 g for 30 min at 4 °C to yield a RNA pellet, followed 
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by two washes with 1 mL of 75% ethanol and centrifugation at 7,500 g for 5 min at 4 °C. 
Finally, ethanol was discarded and the air-dried pellets were resuspended in 80 μL of 
RNase-free water. Total RNA concentration was determined by spectrophotometry using 
Nanodrop 1000. Samples were stored at -80 °C until further analysis.  
3.11 RNA-Seq analysis 
The RNA-Seq data processing and analysis was performed with the help of Eric J.C. 
Galvez, a bioinformatician within Microbial Immune Regulation research group. Total RNA 
isolation from distal colonic tissue was performed as described in 3.10 section. RNA integrity 
was measured in a Bioanalyzer (Agilent Technologies, USA) and samples were selected 
according to RNA Integrity Number (RIN) > 8.5. Isolation of mRNA was performed with 
Dynabeads mRNA DIRECT Micro Kit (Ambion, USA) using 1ug of total RNA. Furthermore, 
cDNA synthesis, fragmentation and sequencing library preparation were done using 
ScriptSeq v2 RNA-Seq Kit (PCR 15 cycles) (Illumina, USA). Sequencing was performed 
through Illumina Hi-Seq 2000 platform in single end mode for 50 bp. An average of 18 
Million of reads per sample (n=8 was obtained). Reads were quality filtered using 
Trimmomatic with the following parameters: (LEADING:3, TRAILING:3, 
SLIDINGWINDOW:4:15, MINLEN:35, HEADCROP:3). After quality control, the reads were 
aligned to the mouse reference genome (mm10) using STAR. Reads count to each gene 
was evaluated using HTseq. Normalization and differential expression were quantified using 
the DEseq2 package. Differential expressed gene networks were analyzed with Consensus 
Path DB-mouse webserver. Data were visualized using ggplot2 R library. 
3.12 Complementary DNA (cDNA) synthesis 
 
One microgram of total RNA was used to generate cDNA using RevertAid Reverse 
Transcriptase, and polyd(T)12-18 primer. Reverse transcription was done as follows: 
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Step Component Volume/Mass 
Final 
concentration 
Step 1 
RNA 1 µg 1 µg 
Oligo(dT)12-18 1 µL 100 pmol 
Add up to 10 µL water and incubate for 5 min at 65 °C 
Step 2 
5X Reaction Buffer 4 µL 1x 
dNTP Mix 2 µL 1 mM 
RevertAid Reverse 
Transcriptase 
1 µL 200 U 
Water 3 µL N/A 
Add 10 µL of reaction mix to RNA and incubate for 60 min at 42 
°C 
Step 3 Incubate for 5 min at 85 °C 
 
Samples were afterwards cooled down (4 °C), diluted 1:10 in water and stored at -20 °C 
until further analysis. 
3.13 Quantitative PCR (qPCR) 
Gene expression analysis was performed using quantitative PCR method. Gene-specific 
probe sets for Casp1, Il18, Ang4, Retnlb, Reg3g, and Hprt were used. Using Kapa Probe 
Fast qPCR Kit, following 10 µL reactions were performed:  
 
Component Volume (µL) Final concentration 
PCR-grade water 0.25 N/A 
KAPA PROBE FAST qPCR 
Master Mix (2x) 
5 1x 
Primer/probe (20x) 0.5 1x 
Template cDNA 4.5 N/A 
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All samples were measured in duplicates on a LightCycler 480 instrument. qPCR conditions 
were as follows:  
 
 
Cycle Step 
Temperature 
(oC) 
Time (s) # of cycles 
Analysis 
mode 
Preincubation 95 60 1 none 
Amplification 
95 3 
40 Quantification 
60 30 
Cooling 37 60 1 none 
 
Results were exported and gene expression was analyzed using the ΔCt method with Hprt 
serving as the reference housekeeping gene. 
3.14 Isolation of lamina propria lymphocytes (LPLs) and 
flow cytometry  
To isolate lamina propria lymphocytes, density gradient centrifugation using Percoll was 
done as previously described203. Intestinal tissues and mesenteric lymph node (MLN) were 
collected on day 0 and day 7 of DSS colitis. Colon and small intestine (SI) were open 
longitudinally and fecal content was removed by washing in 1xPBS. All visible Payers 
patches in the SI were carefully removed.  To remove the epithelial layer, both colon and SI, 
were shaken in 1xHBSS containing 2 mM EDTA for 20 min at 37 oC. Tissues were then cut 
into small pieces and incubated with 5 ml digestion solution (DMEM containing 1% fetal 
bovine serum (FBS), 0.25 mg/ml collagenase D, 0.5 U/ml dispase and 5 mg/ml DNase I) in a 
shaker for 20 min at 37 oC. Digested tissues were filtered through 70 µM cell strainer and 
DMEM + 5% FBS was added to inactivate the enzymes. The digestion step was repeated. 
After centrifugation, cells were resuspended in 4 mL of 40% Percoll and carefully overlaid on 
4 mL of 80% Percoll. Percoll gradient separation was performed by centrifugation at 450 g 
for 25 min at 25 oC. Cells in the interphase, LPLs, were collected, counted and suspended in 
staining buffer. The following antibodies were used: anti-CD45 (30-F11), anti-CD3 (17A2), 
anti-CD4 (RM4-5, GK1.5), anti-CD8a (53-6.7), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-
MHC class II (M5/114.15.2), anti-CD11b (M1/70), anti-CD11c (N418), anti-Ly6G (IA8), anti-
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Ly6C (HK1.4). Live from dead cells were distinguished using AlexaFluor-350 NHS Ester 
staining. Flow cytometry analysis was performed using a BD LSR Fortessa and data were 
analyzed with FlowJo software. 
For detection of intracellular cytokines and transcription factors, isolated LPL cells were 
cultured in enriched DMEM media containing 10% FBS, antibiotic cocktail (100U/ml 
penicillin, 100 µg/ml streptomycin) and 2 mM/ml L-Glutamine for 3h at 37oC. Ex vivo 
stimulations were carried out in the presence of 50 ng/ml phorbol 12-myristate 13-acetate 
(PMA) and 1µg/ml Ionomycin. For intracellular cytokine staining, cells were fixed and stained 
using the Foxp3-staining kit (eBioscience) according to the manufacturer’s instructions. 
Antibodies used for staining were anti-IFNg (XMG1.2) and anti-IL-17A (TC11-18H10.1). 
3.15 Colonoscopy 
Colonoscopy was performed on anesthetized mice using a high-resolution mouse video 
endoscopic system (‘Coloview’, Carl Storz, Tuttlingen, Germany). The severity of colitis was 
scored in a blinded manner using Murine Endoscopic Index of Colitis Severity (MEICS), 
which is based on five parameters: granularity of mucosal surface (0-3); vascular pattern (0-
3); translucency of the colon mucosa (0-3); visible fibrin (0-3); and stool consistency (0-3) 
(Becker et al., 2007). Murine endoscopic colitis scores are described in Table 9.  
 
Table 9 Murine endoscopic colitis scoring 
Score 
Granularity of 
mucosal 
surface 
Vascular 
pattern 
Translucency 
of the colon 
mucosa 
Visible fibrin 
Stool 
consistency 
0 none normal transparent none normal, solid 
1 moderate moderate moderate little still shaped 
2 marked marked marked marked unshaped 
3 extreme bleeding intransparent extreme spread 
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3.16 Histological Evaluation 
Preparation of intestinal tissue samples for histopathological examination was carried out by 
Mouse Pathology core facility at Helmholtz Center for Infection Research. Briefly, intestinal 
tissue samples were placed (cecum) or rolled up to “swiss roles” (colon and small intestine) 
in histology cassettes, fixed in 4% neutrally buffered formaldehyde for a maximum of 48 h, 
and stored in 70% ethanol until processing. Samples were further embedded in paraffin 
according to standard histological procedures and sections of 3 µm thickness were stained 
with hematoxylin-eosin (HE). Stained sections were evaluated under a light microscopy in a 
blind manner. 
 
3.16.1 DSS scoring 
The histological scoring used to evaluate the severity of colitis was adapted from the TJL-
score developed by The Jackson Laboratory204. The alteration of the scores has been 
previously described205. The colon was divided into a proximal, middle and distal section, 
each of about the same size. The three sections were scored for the general criteria: 
severity, degree of ulceration, degree of edema, degree of goblet cell dysplasia, and 
percentage of area involved as described in Table 10. The scores were added up to a total 
of up to 15 per section, or up to 45 per complete colon sample (sum of the scores of the 
three sections). 
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Table 10 Histological scoring of colitis severity 
Score Severity Ulceration Edema 
Goblet cell 
dysplasia 
Area 
involved 
0 no alterations no ulcer no edema no dysplasia 0% 
1 
mild alterations,  
focally small or 
widely separated 
multifocal areas 
of inflammation 
limited to the 
lamina propria 
1-2 ulcers 
(involving up 
to a total of 
20 crypts) 
mild epithelial 
or submucosal 
edema (less 
than the 
muscular layer 
in thickness) 
few goblet 
cells with 
slightly 
increased 
size 
30% 
2 
moderate 
alterations, 
multifocal or 
locally extensive 
areas of 
inflammation 
extending to the 
submucosa 
1-4 ulcers 
(involving a 
total of 20-
40 crypts) 
mild epithelial 
edema 
associated with 
mild 
submucosal 
edema or more 
moderate 
submucosal 
edema (1 to 2 
times as thick 
as the 
muscular layer) 
various, 
irregular 
sizes of 
goblet cells 
40-70% 
3 
severe 
alterations, 
inflammation 
extended to all 
layers of the 
intestinal wall or 
entire intestinal 
epithelium 
destroyed 
any ulcers 
that exceed 
the previous 
every edema 
more extensive 
than the 
previous 
ballooned 
goblet cells, 
crypt 
dilation and 
goblet cell 
depletion 
>70% 
3.17 Treatment of mice with recombinant mouse IL-18 (rIL-
18) 
Each mouse received intraperitoneal (i.p.) injections of 200 ng of mouse recombinant IL-18 
suspended in 200 µL sterile PBS for 8 consecutive days, starting 1 day before 
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administration of DSS in drinking water. Control mice were administered daily with 200 µL of 
sterile PBS. 
3.18 Metabolite measurements  
3.18.1 SCFAs extraction and measurements 
SCFAs were measured and analyzed by Dr. Meina Neumann-Schaal from Leibniz institute 
DSMZ-German Collection of Microorganisms and Cell Cultures. 
Serum and fecal content samples were snap-frozen in liquid nitrogen and stored at -80 °C 
until further processing. For SCFAs extraction colonic and cecal content (50-100 mg) was 
resuspended in 600 µl water spiked with internal standard (2 µl o-cresol/250 ml) and 60 µl 
65% HPLC-grade sulfuric acid per 50 mg fresh weight and mixed vigorously for 5 min. 400 
µl of the mixture were extracted with 200 µl of tert-butyl methyl ether., and the ether phase 
was analyzed by GC-MS as described previously206. Standard curves of organic acids were 
used for external calibration. 
3.18.2 Metabolome extraction 
Metabolites were extracted using an adapted protocol207. Briefly, cecal content (50-100 mg) 
was collected in tubes containing glass and ceramic beads mix (Bertin-corp) and 
appropriate volume (1000 µL/100 mg cecal content) of -20 °C ice-cold extraction fluid 1 
(methanol+H2O, 4+1) containing 32 µM U
13C ribitol as internal standard was added. 
Homogenization was performed with a Retsch mill (3x 2 min at 30 Hz/sec). An appropriate 
volume (500 µL/100 mg cecal content) of extraction fluid 2 (H2O containing 2 µg/mL D
6-
glutaric acid) was added and samples were mixed for 10 sec. Chloroform (800 µL/100 mg 
cecal content) was added and samples were again mixed for 30 sec prior agitation for 15 
min at 1400 rpm and 4 °C in a tube shaker. After centrifugation for 5 min at 4 °C and 13.000 
rpm, 60 µL of the upper polar phase was transferred to a GC vial with micro insert. Solvents 
were evaporated at 4 °C in a rotary vacuum evaporator until total dryness. Sample tubes 
were capped and stored at -80 °C until further processing. 
Methods 
 
 
51 
 
3.18.3 Targeted metabolome GC-MS analysis 
Targeted metabolome measurements and analysis was performed with by Dr. Kerstin 
Schmidt-Hohagen from the Department of Bioinformatics and Biochemistry at Technische 
Universität Braunschweig 
Online metabolite derivatization was performed using an Axel Semrau Autosampler. Dried 
polar metabolites were dissolved in 15 μL of 2% methoxyamine hydrochloride in pyridine at 
40°C under shaking. After 90 min, an equal volume of N-methyl-N-(trimethylsilyl)-
trifluoracetamide (MSTFA) was added and held for 30 min at 40 °C. 
Sample (1 µL) was injected into an SSL injector at 270 °C in splitless mode. GC-MS 
analysis was performed using an Agilent 7890A GC equipped with a J&W 30m DB-35MS 
capillary column (0.25 mm inner diameter, 0.25 µm film thickness). Helium was used as 
carrier gas at a flow rate of 1.0 mL/min. The GC oven temperature was held at 90 °C for 1 
min and increased to 320 °C at a rate of 15°C/min and held at that temperature for 8 min, 
resulting in a total run time of 25 min per sample. The GC was connected to an Agilent 
5975C MS operating under electron impact ionization at 70 eV. The transfer line 
temperature was set to 280 °C. The MS source was held at 230 °C and the quadrupole at 
150 °C. The detector was operated in SIM mode. The detailed settings for each metabolite 
are summarized in Table 11. Tuning and maintenance of the GC-MS was done according to 
the supplier´s instructions, an automated tuning routine was applied every 150 injections. 
Data processing was done using the MetaboliteDetector software208. 
 
Table 11: Settings applied in SIM mode. 
Metabolite Derivatization Ions 
Cadaverine 4TMS 130.0, 174.0, 375.0 
Histamine 3TMS 174.0, 226.0, 312.0 
Putrescine 4TMS 174.0, 214.0, 361.0 
Spermidine 5TMS 116.0, 144.0, 156.0 
Spermine 6TMS 144.0, 174.0, 329.0 
U13C-Ribitol (IS) 5TMS 207.0, 220.0, 323.0 
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3.19 Bone marrow-derived macrophage (BMDM) 
preparation 
Bone marrow cell suspensions were isolated by flushing femurs and tibias of 8- to 12-week-
old WT or TLR4-deficient mice with ice-cold, sterile 1x PBS. Cells were further centrifuged at 
1500 rpm for 10 min at 4 °C, resuspended in BMDM Medium and counted. Ten million cells 
were seeded per 10 cm petri dish in 10 ml BMDM Medium and cultured in a humidified 
incubator at 37 °C, 5% CO2. Every 2 days medium was replaced with fresh, pre-warmed 
BMDM Medium. After 6 days, adherent cells were washed in ice-cold, sterile 1x PBS and 
incubated at 4 °C for 10 min in 3 ml of 50 mM EDTA/PBS to detach them from the surface. 
Next, cells were harvested by gently scraping and washed in additional 25 ml PBS. Fifty 
thousand cells were seeded in each 96-well. 
3.19.1 Preparation of L292 cell supernatants 
L292 cells were grown in 20 ml of DMEM Complete (DMEM + 10% FBS + L-glutamine) per 
T175 flasks, in a humidified incubator at 37 °C, 5% CO2. After washing with sterile 1x PBS, 
fully confluent cells culture was detached from the surface using 2-3 ml of 1xTrypsin/EDTA 
and centrifuged at 1,500 rpm, for 10 min, at 4 °C. Cells were split in 1:4 ratios into new T175 
flasks, and at fully confluency, the supernatant was collected every 2 days and stored at -20 
°C until further use for BMDM Medium preparation. 
3.20 Preparation of bacterial extracts 
Fecal content (colon and cecum) from SPF and SPF+P. intestinalis mice were suspended in 
sterile PBS and filtered through 70 µm cell strainer (BD Falcon). Homogenized content was 
normalized to 0.5 mg/ml and centrifuged for 5 min at 10,000 rpm. Supernatant were 
collected for BMDM stimulation (Secreted microbial component) and bacterial pellet was 
suspended in 1 ml PBS with CaCl2 and MgCl2, freeze/thawed 3 times, sonicated for 2 
minutes and incubated at 65 °C for 1 hour. Cell lysate was centrifuged and pellet was 
suspended in 1 ml DMEM and 10 µl was used for BMDM stimulation (Microbial community) 
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for 12 h. P. intestinalis and B. acidifaciens cultures at OD600=0.2 were centrifuged and 
bacterial pellets were lysed as described for microbial community. 
3.21 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 program (GraphPad Software, 
Inc.) and R v3.3.0. Data are expressed as mean ± SEM (Standard error of mean). 
Differences were analyzed by Student’s t test and ANOVA. P values indicated represent an 
unpaired nonparametric Mann-Whitney or two-way ANOVA by Tukey´s multiple comparison 
analysis. The permutational multivariate ANOVA analysis of variance (ADONIS) was 
computed with 999 permutations. In addition to p value, for ADONIS tests an R2 > 0.1 (effect 
size, 10%) was considered as significant. P values ≤ 0.05 were considered as significant: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Results 
 
4.1 Isolation and characterization of distinct Prevotella 
spp. from mouse intestine 
Alteration in the microbiota of some lines of Nlrp6-/- mice renders them more susceptible to 
chemically-induced intestinal inflammation and a high relative abundance of unknown 
members of the family Prevotellaceae was identified by 16S rRNA gene sequencing in mice 
with high disease susceptibility18. In addition, we identified that different species of the genus 
Prevotella were also highly abundant in other colitogenic communities of WT mice from 
distinct commercial vendors67. Yet, whether these species actively propagate inflammation 
in the intestine remained to be investigated. In order to experimentally address these 
questions, we attempted to isolate novel Prevotella species from the colon content of these 
mouse lines using a step-wise enrichment and targeted isolation procedure under strictly 
anaerobic conditions (Figure 3).  
 
Figure 3: Isolation of Prevotella spp. 
Scheme of the step-wise enrichment and targeted isolation procedure of Prevotella spp. under 
anaerobic conditions. 
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The cultivation effort yielded three new species belonging to the genus Prevotella based on 
the comparison of their 16S rRNA genes to other described Prevotella species (Figure 4). 
Based on genotypic characterization we propose that the isolates belong to novel bacterial 
taxons within the genus Prevotella, for which the names Prevotella intestinalis, Prevotella 
rodentium, and Prevotella muris are proposed. Out of these three species, one P. 
intestinalis (OTU_16) showed the highest similarity to the most prevalent human intestinal 
Prevotella species, namely P. copri 209. 
Figure 4: Phylogenetic characterization of novel Prevotella isolates 
Phylogenetic tree based on 16S rRNA sequences showing the positions of novel Prevotella species 
within the genus Prevotella.  
 
Isolated species demonstrated distinct in vitro growth rates as well as distinguishable 
colonies forms and sizes on agar plates. While Prevotella rodentium and Prevotella muris 
demonstrated optimal growth in BHI-S medium (highest OD600 P. rodentium =1.703, P. 
muris=1.878), P. intestinalis cultures are characterized by a low turbidity with highest OD600 
≤0.414) suggesting distinct in vitro growth requirements (Figure 5A). P. intestinalis 
demonstrated the slowest growth rate, reaching the stationary phase after 58 h, whereas 
stationary phase was reached by P. rodentium and P. muris at 24 h and 34 h of growth, 
respectively.  
After 72 h of growth at 37 °C on BHI+blood+vitamin K-agar plates under anaerobic 
conditions, P. intestinalis colonies are circular, pinpoint and translucent to slightly opaque, 
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whereas P. rodentium forms circular, small to moderate, convex, shiny grey colonies (Figure 
5B). P. muris growth was not detectable in BHI+blood+vitamin K-agar plate, however it 
forms circular, small to moderate, shiny, creamy colonies on BHI+FBS+vitamin K-agar 
plates (Figure 5B).  
 
Figure 5: Distinct growth rate and phenotypical differences of novel Prevotella 
isolates  
Prevotella growth curves in BHI-S medium (A) and colony growth on BHI+blood+vitamin K- or 
BHI+FBS+vitamin K-agar plates (B). 
 
A detailed comparative genome analysis of new Prevotella species was performed by Eric 
J.C. Galvez as a part of his PhD research project (data unpublished). In brief, whole 
genome sequencing and assembly functionally assigned 72% of the genomes (in average) 
to known features. Interestingly, P. intestinalis presented the highest number of unique 
features, some of them being potential virulence factors such as metalloproteases (i.e. 
peptidase M6) and cysteine-type peptidase. 
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4.2 Impact of Prevotella spp. colonization on intestinal 
ecosystem 
4.2.1 Colonization of WT SPF and in vivo fitness of Prevotella 
spp.  
To study the impact of Prevotella spp. on the host, we colonized specific pathogen free 
(SPF) WT mice, devoid of any Prevotella species, by single oral gavage of freshly grown 
culture. After 4-5 weeks Prevotella colonization was determined by analyzing fecal 
microbiota composition using 16S rRNA gene sequencing. Interestingly, all Prevotella spp. 
colonized SPF mice in high relative abundances; P. intestinalis (43.4% +/- 5.8, mean +/- 
SEM), P. rodentium (30.4% +/- 2.9, mean +/- SEM), and P. muris (24.4% +/- 2.5, mean +/- 
SEM) (Figure 6A). In contrary to low in vitro fitness, P. intestinalis colonized SPF mice in the 
highest relative abundance in comparison to other Prevotella species.  
 
Figure 6: Prevotella spp. in vivo growth and interspecies competition in WT SPF mice 
Relative abundance of Prevotella species in feces of WT SPF mice 4 weeks after colonization, as 
quantified using 16S rRNA gene sequencing (A). SPF mice were colonized with equal amounts of all 
three Prevotella isolates and interspecies competition was determined using 16S rRNA gene 
sequencing (P. intestinalis vs P. rodentium statistical test) (B). Data shown as mean ± SEM. P values 
indicated) represent an unpaired nonparametric Mann-Whitney *p < 0.05; **p < 0.01; ***p< 0.001; 
****p< 0.0001.  
 
In order to compare the fitness of the Prevotella isolates between each other in vivo and to 
understand whether they occupy the same niche in the intestine, we performed an 
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interspecies in vivo competition assay by colonizing SPF mice with the same amounts of all 
three Prevotella species. Analysis of relative abundance of P. intestinalis, P. rodentium, and 
P. muris on day 0, 1, 2, 4, 7, and 14 days post colonization clearly demonstrated the 
interspecies competition in vivo. Relative abundance of P. intestinalis was the highest 
throughout the time course of the experiment, outcompeting the other two Prevotella 
species (Figure 6B). While P. muris abundance was under the detection limit, P. rodentium 
demonstrated the ability to coexist with dominant P. intestinalis species, however in 
significantly lower abundance than when colonizing SPF microbiota alone (Figure 6A and 
6B. These data suggest Prevotella species share similar metabolic niches within the mouse 
intestine, with P. intestinalis demonstrating the highest in vivo fitness among the compared 
species. In vivo transcriptome analysis by Eric J.C. Galvez suggested in vivo fitness in 
Prevotella species correlates with the number of polysaccharide utilization loci (PULs), with 
P. intestinalis expressing the highest number. 
Based on the highest genomic similarity to the predominant human gut Prevotella species - 
P. copri, and demonstrated highest in vivo fitness, we selected P. intestinalis isolate as a 
representative species to further study the impact of Prevotella spp. on the intestinal 
ecosystem and the host. 
4.2.2 P. intestinalis reshapes the intestinal microbial 
community structure  
To further study the impact of P. intestinalis on the intestinal ecosystem, we colonized 
specific pathogen free (SPF) WT mice, devoid of any Prevotella species, by a single oral 
gavage of a freshly grown culture. After 4-5 weeks P. intestinalis colonization was 
determined by analyzing fecal microbiota composition using 16S rRNA gene sequencing. 
Analysis of β-diversity using principle coordinates analysis (PCoA) showed distinct 
clustering of SPF and SPF+P. intestinalis communities (Figure 7A). Based on permutational 
multivariate analysis of variance (ADONIS), over 60% of the differences were attributed to 
Prevotella colonization (R2 = 0.62, p<0.001). Strikingly, P. intestinalis colonized SPF mice in 
high relative abundance (50.8% +/- 3.8, mean +/- SEM) (Figure 7B), thereby significantly 
reshaping the microbial community including a decreased Firmicutes to Bacteroidetes ratio 
(F/B) (Figure 7C). Although there was no difference in the observed species richness 
(p=0.26), the complexity of the community structure, when accounting for species richness 
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and evenness (Shannon index), was significantly lower in SPF mice after P. intestinalis 
colonization (p<0.0001) (Figure 7D). On a family level, comparison of SPF communities with 
and without P. intestinalis colonization by linear discriminant analysis (LDA) effect size 
(LEfSe) showed that Prevotella colonization decreased relative abundance of resident 
families within the Deferribacteres and Bacteroidetes phyla, as well as most of the 
Firmicutes (Figure 7E).  
 
Figure 7: P. intestinalis colonization reshapes the resident SPF community 
Analysis of β-diversity (PCoA) using Bray-Curtis distances along with multivariate analysis of variance 
(ADONIS test) of variables ‘microbiota, and ‘cage’ (A) and fecal microbiota composition on the family 
level using 16S rRNA gene sequencing (B). α-diversity (Observed and Shannon) in SPF and SPF+P. 
intestinalis mice (Student t-test) (C). Ratio of relative abundances between Firmicutes and 
Bacteroidetes (F/B) (D) and analysis of differentially abundant bacterial families in SPF+P. 
intestinalis microbiota by LEfSe (Kruskal-Wallis test p<0.05, LDA 4.0) (E). The results are shown as 
mean ± SEM from three independent experiments. P values indicated represent an unpaired 
nonparametric Mann-Whitney test if not indicated differently *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 
0.0001. 
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4.2.3 Biogeography of P. intestinalis colonization 
Prevotella spp. have been found to predominantly colonize the lumen of the lower 
gastrointestinal tract (GIT)37,210, but have been as well described as a part of the intestinal 
mucosal community211,212. In order to investigate the extent to which the fecal microbiota of 
SPF+P. intestinalis mice reflects the composition of luminal sites, we analyzed the microbial 
composition in the lumen of distal (DC) and proximal (PC) colon, cecum (CEC), and small 
intestine (SI) with the focus on P. intestinalis abundance (Figure 8A). Comparably to stool 
samples, P. intestinalis was found in high relative abundance in DC (52.3% +/- 4.7, mean +/- 
SEM), PC (52.5% +/- 5.6, mean +/- SEM), and CEC (37% +/- 1.4, mean +/- SEM). In 
contrast, P. intestinalis was found in significantly lower relative abundance in SI (2% +/- 0.7, 
mean +/- SEM, p=0.002), likely to reflect the physiological differences within distinct 
gastrointestinal sites, including pH, oxygen gradient, and antimicrobial components213. 
The combination of 16S rRNA gene sequencing with the quantitative profiling of microbial 
loads has recently described variation within the absolute abundances of intestinal bacteria 
and linked it to enterotypes in healthy humans214. Hence, we quantified bacterial loads using 
flow cytometry-based enumeration of bacterial concentrations in the luminal content. This 
revealed no differences in the total bacterial cell counts after Prevotella colonization 
suggesting that Prevotella is not simply increasing the total microbial density, but rather 
replaces other bacteria (Figure 8B). We additionally analyzed the composition of the 
mucosa-associated microbiota in DC and PC, locations with highest P. intestinalis 
colonization. We found P. intestinalis to be present in both DC and PC mucosal sites, with 
higher abundance in DC (23.9% +/- 2.6, mean +/- SEM), yet significantly lower than in the 
DC lumen (Figure 8C).  
Altogether, these data demonstrates that P. intestinalis colonization has a significant impact 
on SPF community structure, including the decrease in the microbial diversity and 
Firmicutes to Bacteroidetes ratio. In addition, P. intestinalis predominantly colonizes the 
lumen of colon and cecum, and can be found closely associated to the colonic mucosa, 
which is in line with previous findings regarding the niche of Prevotella spp. and where it 
may exert immunomodulatory effects on the host135. 
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Figure 8: Biogeography of intestinal colonization by P. intestinalis  
Intestinal microbiota composition in the stool, lumen of distal (DC) and proximal (PC) colon, cecum 
(CEC), and small intestine (SI), and DC and PC mucosa (A), and flow cytometric enumeration of 
microbial cells in luminal content (cecum and colon) of SPF and SPF+P. intestinalis mice (B). Relative 
abundance of P. intestinalis in the mucosa of DC and PC colon (C). Data shown as mean +/- SEM. *p 
< 0.05; **p < 0.01 performed with unpaired nonparametric Mann-Whitney test.  
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4.3 P. intestinalis induces minor changes in the host 
transcriptome in the intestine  
Members of the intestinal microbiota are known modulators of the host immune responses 
which can lead to the development of the inflammatory diseases67,215. In order to investigate 
whether Prevotella-induced changes in the microbiota of SPF mice induce significant 
alterations in the host gene expression, we performed RNA sequencing (RNA-seq) for host 
transcriptome analysis in the colon of SPF and SPF+P. intestinalis mice. 
A principal component analysis of gene expression profiles revealed significant difference 
between SPF and SPF+P. intestinalis mice (Figure 9A). However, the analysis of 
differentially expressed genes (log2 fold change >2.0; p<0.05) demonstrated only minor 
effects of Prevotella colonization on the tissue transcriptome (Figure 9B). In Prevotella-
colonized mice, we identified 35 upregulated and 27 downregulated genes when compared 
to the SPF untreated mice (Figure 9C). Some of the upregulated genes include genes 
important for cytokine and chemokine signaling (IL22ra2, Cxcr5), B cell development, 
differentiation, and activation (Cd19, Cd79b, Tnfrsf13c, Ms4a1), T cell proliferation 
(Tnfrsf13c). Moreover, Prevotella colonization of SPF mice resulted in upregulation of the 
Ubd gene (encoding the Ubiquitin-Like Protein FAT10) expression, which had been reported 
to be inducible by TNF-α and IFN-γ, and implicated to play a role in numerous cellular 
processes, including NF-kB activation and caspase-dependent cell death216–218. Surprisingly, 
several genes upregulated in Prevotella-colonized mice are known to be expressed in a 
circadian pattern and form a core component of the circadian clock (Per2, Per3, Ciart). 
In addition, pathway enrichment analysis based on gene ontology (GO) showed that many 
upregulated genes in Prevotella-colonized mice were involved “Immune system processes” 
and “B cell activation” (Figure 9D). These data suggests P. intestinalis may have immuno-
modulatory effects on the host, however further experimental validation is necessary to 
substantiate the specific findings. Whether P. intestinalis colonization indeed activates B 
cells or impacts T cell proliferation will be assessed by global immunophenotyping. 
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Figure legend on the next page 
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Figure 9: Prevotella-induced host transcriptome changes in colon tissue of SPF and 
SPF+P. intestinalis mice 
SPF mice were colonized with P. intestinalis for 5 weeks and host transcriptome analysis was 
performed from distal colon tissue of SPF and P. intestinalis mice. Principal component analysis of 
gene expression profile by RNAseq (A). Log ratio and mean average plot (MA-plot,). Gene 
expression levels in non-colonized SPF mice vs. SPF colonized with P. intestinalis. Colored dots 
indicate genes with log2 fold change >2.0; p<0.05. RED – upregulated in SPF+P. intestinalis, BLUE - 
upregulated in SPF control (B). Heatmap displays the read counts of significant differentially 
expressed genes (C). Pathway enrichment analysis based on gene ontology (GO) using upregulated 
genes in SPF+P. intestinalis (D).  
4.4 P. intestinalis colonization exacerbates intestinal 
inflammation  
Increased abundance of P. intestinalis, at that time described as an unknown and 
uncultured member of the intestinal microbiota in NLRP6-deficient mice, was associated 
with higher susceptibility to chemically-induced colitis18. In addition, presence of Prevotella 
species was described in distinct lines of immunocompetent mice prone to intestinal 
inflammation67. While these effects were not causally linked to the presence of Prevotella, 
the data suggested that a Prevotella-dominated microbiome may have the propensity to 
promote inflammation and intestinal dysbiosis. 
4.4.1 P. intestinalis colonization alters susceptibility to DSS-
induced colitis in immunocompetent host 
We next wanted to investigate whether P. intestinalis colonization by P. intestinalis of SPF 
community is sufficient to alter the susceptibility to intestinal inflammation after induced 
damage to the intestinal barrier. Notably, WT SPF mice used in this study have been 
previously reported to be relatively resistant to induction of DSS colitis, displaying moderate 
colitis severity and mild weight loss67. Therefore, we colonized 5 weeks old WT SPF mice 
with a single oral gavage of P. intestinalis culture and, after 5 weeks of colonization, acute 
intestinal inflammation was induced by administering dextran sulfate sodium (DSS) in 
drinking water (2.1% w/v). Colonization of SPF mice with P. intestinalis resulted in more 
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severe disease outcome as displayed by the significant increased body weight loss when 
compared to control SPF mice (Figure 10A). However, mice colonized with P. intestinalis did 
not show an increase in mortality (Figure 10B). Colonoscopy on days 6 and 9 after induction 
of DSS colitis revealed increased tissue damage in P. intestinalis colonized mice (Figure 
10C and 10D). 
Figure 10: P. intestinalis colonization alters the colitis susceptibility of WT SPF mice 
Body weight loss (A) and survival (B) of WT mice harboring SPF and SPF+P. intestinalis microbiota 
during DSS colitis (2.1 % w/v for 7 days). Representative colonoscopy images of colitis severity (C) 
performed on day 6 after colitis induction in SPF and SPF+P. intestinalis mice and colitis score (D) on 
day 6 and day 9 of DSS colitis, based on five parameters: granularity of mucosal surface, vascular 
pattern, translucency of the colon mucosa, visible fibrin and stool consistency. Colon length (E) during 
steady state (d0) and DSS (d7). The results are shown as mean +/- SEM. *p < 0.05; **p < 0.01***p< 
0.001; ****p< 0.0001 performed with unpaired nonparametric Mann-Whitney test. 
 
Moreover, higher intestinal inflammation of Prevotella-colonized mice was supported by 
pronounced colon shortening (Figure 10E) and histological characterization of tissue 
damage during DSS colitis (Figure 11). Whereas the histological analysis of cecum and 
small intestine during DSS colitis showed no significant differences between SPF and 
SPF+P. intestinalis mice (Figure 11A and 11B), Prevotella colonization induced significant 
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inflammation in the colon (Figure 11C). Inflammation in P. intestinalis colonized mice was 
highest in the distal colon with pronounced tissue erosion, higher hyperplasia, edema, and 
infiltration of inflammatory cells (Figure 11D and 11E). Notably, histological analysis of 
colonic tissue between SPF and Prevotella-colonized mice revealed no differences during 
steady state (Figure 11D and 11E). Together, these data demonstrate that P. intestinalis is 
able to alter susceptibility to DSS colitis even in an immunocompetent host. 
Figure 11: Histological evaluation of colitis severity in SPF and SPF+P. intestinalis 
mice. Histological evaluation of small intestine (A), cecum (B), and colon (C) in SPF and 
SPF+P.intestinalis mice measured during steady state (d0) in colon and during DSS colitis (d7). 
Representative images of H&E-stained distal colon sections on d0 and d7 of DSS colitis (D), and 
histological analysis of d7 distal colon sections by each scoring parameter (E). The results are shown 
as mean +/- SEM. *p < 0.05; **p < 0.01***p< 0.001; ****p< 0.0001 performed with unpaired 
nonparametric Mann-Whitney test. 
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4.4.2 Altered DSS susceptibility by P. intestinalis colonization 
is associated with elevated pro-inflammatory cytokine 
responses 
To further characterize the differences in inflammation between SPF and SPF+P. intestinalis 
mice, various cytokines and chemokines were quantified in the distal colon tissue in steady 
state and during inflammation. Levels of the pro-inflammatory cytokines IL-6 and tumor 
necrosis factor alpha (TNF-α) were higher in mice harboring P. intestinalis (Figure 12) on 
day 7 of DSS colitis. P. intestinalis colonization also resulted in increased levels of the anti-
inflammatory cytokine IL-10 in the colon. Notably, contrary to the results observed in SPF 
mice colonized with the Prevotella-rich microbial community from Nlrp6-/- mice from which P. 
intestinalis was originally isolated67, mice colonized with P. intestinalis alone did not display 
increase in levels of interferon (IFN)- γ, IL-17A, IL-1β, or CCL5 (Figure 12). 
Figure 12: Production of pro-inflammatory cytokines during steady state and DSS 
colitis in SPF and Prevotella-colonized mice 
Concentration of cytokines measured from distal colon tissue homogenates of SPF and SPF+P. 
intestinalis mice on day 0 and day 7 of DSS, analyzed using LEGENDplex kit or ELISA (IL-18). Data 
represented as mean +/- SEM. *p < 0.05; **p < 0.01 performed with unpaired nonparametric Mann-
Whitney test. 
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Strikingly, there was no impact of P. intestinalis colonization on levels of a range of 
cytokines tested during the steady state when compared to the SPF mice, except a 
decrease of IL-18 levels in distal colons of Prevotella-colonized mice. Higher intestinal 
inflammation in SPF+P. intestinalis mice during DSS colitis was also characterized by 
significant increase of multiple chemokines, including LIX and MCP-1, which have been 
involved in the recruitment and activation of monocyte and neutrophils to the site of 
inflammation, as well as MIP-1α and MIP-1β (Figure 13).  
Figure 13: Production of pro-inflammatory chemokines during steady state and DSS 
colitis in SPF and Prevotella-colonized mice 
Concentration of chemokines measured from distal colon tissue homogenates of SPF and SPF+P. 
intestinalis mice on day 0 and day 7 of DSS, analyzed using LEGENDplex kit or ELISA (IL-18). Data 
shown as mean +/- SEM. *p < 0.05; **p < 0.01 performed with unpaired nonparametric Mann-Whitney 
test. 
 
4.4.3 Prevotella-induced inflammation is associated with 
elevated neutrophil infiltration 
Inflammation in DSS colitis can be triggered by different effector cells including innate and 
adaptive immune cells67,219. To identify which subsets of immune cells are differently present 
between the two groups, we analyzed the abundance and composition of colonic lamina 
propria leukocytes (cLPLs) before and 7 days after induction of DSS colitis by flow 
cytometry. The analysis of the innate cLPLs (Figure 14A) showed that Prevotella 
colonization resulted in increased frequency and numbers of LPLs (CD45+ cells) after the 
DSS induction, but no difference was observed between SPF and Prevotella-colonized mice 
during the steady state (Figure 14B and 14C). Analyzing the abundance of various subsets 
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of innate immune cells, we observed a significant increase in frequency and numbers of 
neutrophils (Ly6C+Ly6G+ cells) in colons of mice colonized with P. intestinalis during DSS 
colitis, but not in the steady state (Figure 14D-F). These findings are in line with the 
increased levels of multiple neutrophil-attracting chemokines we measured in colons of 
SPF+P. intestinalis mice (Figure 13A). We observed no significant increases in 
MHCII+CD11b+CD11c- or MHCII+CD11c+CD11b+/- cells, containing both macrophages 
and dendritic cells (Figure 14G).  
The global analysis of immune cells subsets of the adaptive immune system in colon tissue 
demonstrated no significant differences in cell numbers or frequencies (Figure 15A), i.e. we 
observed no differences in the numbers and abundances of total CD4+ and CD8+ T cells 
(Figure 15B-C) as well as B220+ B cells (not shown). Notably, while the numbers and 
frequency of activated CD4+ T cells (CD62L-CD44+) were increased in colons of Prevotella-
colonized mice during DSS colitis (Figure 15D and 15E), the numbers of different CD4+ T 
helper (Th) subsets including Th1 (CD4+IFN-γ+) and Th17 (CD4+IL-17+) cells as well as in 
regulatory T cells (CD4+Foxp3+) were not affected (Figure 15F-H). These data suggest that 
exacerbation of DSS colitis severity by P. intestinalis is associated with differential 
recruitment and activation of innate and to a lesser degree of adaptive immune cells, 
respectively.  
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Figure 14: Analysis of innate colonic LPLs in SPF and SPF+P. intestinalis mice    
Colonic lamina propria leukocytes (cLPLs) were isolated from WT mice harboring SPF and SPF+P. 
intestinalis microbiota, during the steady state (d0) and on day 7 (d7) during DSS colitis, and 
analyzed by fluorescence-activated cell sorting (FACS). Gating strategy of FACS data is displayed for 
panel of innate cells (A). Frequency (B) and total number of CD45+ cells in cLPLs (C). Representative 
FACS plots of analysis of neutrophil infiltration upon DSS induction (d7) (D), and frequencies (E) and 
total numbers (F) of neutrophils on d0 and d7 DSS. Total cell numbers of CD11b+ (G) and CD11c+ 
(H) cells. The results are shown as mean +/- SEM. *p < 0.05 performed with unpaired nonparametric 
Mann-Whitney test. 
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Figure 15: Analysis of T cell subsets in SPF and SPF+P. intestinalis mice in steady 
state and DSS-induced colitis 
Colonic lamina propria leukocytes were isolated from WT mice harboring SPF and SPF+P. 
intestinalis microbiota, during the steady state (d0) and on day 7 (d7) during DSS colitis, and 
analyzed by FACS. Gating strategy of FACS data are displayed for panel of adaptive cells (A). Total 
number of CD8+ (B), CD4+ (C), and activated (CD44+) T cells (D) in cLPLs. Representative FACS 
plots of analysis of activated T cells on day 7 during DSS (E), and total numbers of subsets of helper 
T cells (F-H) on d0 and d7 DSS. Data shown as mean +/- SEM. *p < 0.05 performed with unpaired 
nonparametric Mann-Whitney test. 
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4.4.4 Prevotella-induced inflammation is independent of 
adaptive immunity 
We recently demonstrated that the colitogenic community of Nlrp6-/- mice, which contains P. 
intestinalis, alters susceptibility to DSS colitis via modulation of adaptive immune cells, i.e. 
the transfer of the community in Rag2-/- mice was unable to exacerbate disease severity67. 
To test whether P. intestinalis requires the presence of adaptive immune cells to alter colitis 
susceptibility, we colonized WT and Rag2-deficient mice with P. intestinalis. Importantly, 
both WT and Rag2-/- mice harbored the same SPF microbiota before the P. intestinalis 
colonization (Figure 16A and 16B). Specifically, the comparison of their fecal microbiota 
composition before induction of DSS colitis showed that the mice clustered together in 
relation to their microbial communities (SPF or SPF+P. intestinalis) (Figure 16B). 
Multivariate analysis of variance using ADONIS showed microbiota contributed to the 
variability of the groups with 60% (R2=0.60, p=0.001), while genotype contributing to the 
differences as little as 5% (R2=0.05, p=0.007). Strikingly, P. intestinalis exacerbated DSS 
colitis severity both in WT and Rag2-/- mice, as indicated by their weight loss (Figure 16C) 
and colon shortening (Figure 16D). Taken together, these results show that P. intestinalis 
colonization promotes intestinal inflammation upon damage to the intestinal barrier 
independent of adaptive immune cells. 
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Figure 16: Prevotella-exacerbated intestinal inflammation is independent of adaptive 
immune system  
WT and Rag2
-/-
 mice with SPF microbiota were left untreated or colonized with P. intestinalis for 5 
week before induction of DSS colitis  Analysis of β-diversity (PCoA) of WT and Rag2
-/-
 harboring SPF 
and SPF+ P. intestinalis mice along with multivariate analysis of variance (ADONIS test) of variables 
‘microbiota’, ‘genotype’ and ‘cage’ (A) and fecal microbiota composition analysis of SPF WT and 
Rag2
-/- 
mice on the family level using 16S rRNA gene sequencing (B). Body weight loss during DSS 
colitis (2.1 % for 7 days) (C) and colon length on day 7 (D). Data shown as mean +/- SEM. *p < 0.05; 
**p < 0.01 performed with unpaired nonparametric Mann-Whitney test if not indicated differently. 
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4.4.5 Alteration of the microbiota composition during DSS 
colitis 
Induction of DSS colitis has been shown to alter the composition of the intestinal 
microbiota220. To analyze the impact of induction of DSS colitis on the microbiota 
composition of SPF and SPF+P. intestinalis mice, and investigate whether intestinal 
inflammation further promotes Prevotella abundance in the gut, we analyzed the microbiota 
composition before and during DSS colitis. Comparison of fecal microbial communities in 
SPF and SPF+P. intestinalis mice before (d0) and after induction of DSS colitis (d6) reveled 
significant changes due to induction of DSS colitis (Figure 17A and 17B). The permutational 
multivariate analysis of variance (ADONIS) showed that 43% of the differences were due to 
induction of inflammation by DSS treatment (R2 = 0.43, p<0.001). Microbiota composition of 
SPF and Prevotella-colonized mice during DSS colitis was characterized by significant 
decrease of α-diversity, with decrease in specie richness and evenness (Figure 17C).  We 
used the linear discriminant analysis effect size (LEfSe) method to identify the most 
differentially abundant bacterial families between steady state and during induction of DSS 
in SPF+P. intestinalis mice. Even though we have not observed significant change in 
Prevotella abundance between steady state and during DSS colitis, relative abundance of 
other members of the Erysipelotrichaceae, Porphyromonadaceae, Lactobacillaceae, and 
Ruminococcaceae families were increased during inflammation (Figure 17D). In order to 
determine whether increase in abundance of these bacterial families contributes to the 
higher susceptibility to DSS colitis we compared differentially abundant families between the 
SPF and SPF+P. intestinalis mice during inflammation. The LEfSe analysis revealed 
Prevotellaceae as the only differentially abundant member (Figure 17E), whereas other 
members showed no significant differences and comparable relative abundance in both SPF 
and SPF+P. intestinalis mice. These data suggest that Prevotella colonization, rather than 
the increase in abundance of resident members of the SPF microbial community, is 
responsible for increased susceptibility to intestinal inflammation. 
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Figure 17: DSS-induced changes in the microbiota of Prevotella-colonized mice  
Analysis of β-diversity (PCoA) along with multivariate analysis of variance (ADONIS test, ***p < 
0.001.) along with multivariate analysis of variance (ADONIS test) of variables ‘microbiota’, ‘treatment’ 
and ‘cage’ (A), fecal microbiota composition on the family level using 16S rRNA gene sequencing (B), 
and α-diversity (C) in SPF and SPF+P. intestinalis mice during steady state (d0) and DSS-colitis (d6). 
LEfSe analysis of differentially abundant families between d0 and d6 of DSS colitis on microbiota of 
SPF+P. intestinalis mice (D) and between SPF and SPF+P. intestinalis mice on d6 of DSS colitis (E) 
(Kruskal-Wallis test p<0.05, LDA 4.0).  
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4.5 Investigation of P. intestinalis immunogenic properties 
 
We have shown that P. intestinalis colonization alters SPF intestinal community and 
increases its susceptibility to intestinal inflammation. Whether P. intestinalis colonization 
remodels the microbial community of SPF mice to a more pro-inflammatory composition or 
increased susceptibility to intestinal inflammation is rather attributed to higher 
immunogenicity and immuno-stimulatory potential of P. intestinalis, remained to be 
investigated. 
 
4.5.1 P. intestinalis monocolonization of germ-free mice 
We next wanted to determine P. intestinalis immuno-stimulatory potential by using germ-free 
(GF) mice and excluding the effect of the microbiota alteration. We therefore monocolonized 
GF mice with P. intestinalis and tested for colonization in GF and control SPF mice 7 days 
after oral gavage (Figure 18A). Surprisingly, no colonization by P. intestinalis could be 
detected in GF mice by Prevotella-specific PCR, whereas control SPF mice were colonized 
as expected (Figure 18B). Further examination of colon sections of GF and SPF mice 
colonized by Prevotella by electron microscopy showed absence of bacteria in both groups 
(Figure 18C) suggesting that P. intestinalis is not able to colonize GF mice. Whether inability 
to colonize GF mice is a result of lack of microbial cooperation and cross-feeding on 
nutrients produced by other members of the microbiota, or unfavorable physical and/or 
chemical properties in GF intestine, such as increase of oxygen levels, remained unclear. 
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Figure 18: Monocolonization of germ-free mice by P. intestinalis 
GF and SPF mice were colonized by oral gavage with P. intestinalis for 7 days (A) and colonization 
was determined by Prevotella-specific PCR from fecal DNA (B).  Electron microscopy images of colon 
sections in GF (left) and GF+P. intestinalis mice (right) (C). 
4.5.2 TLR4 senses P. intestinalis and triggers a pro-
inflammatory immune response in vitro 
To answer the question whether P. intestinalis colonization remodels the microbial 
community of SPF mice to a more pro-inflammatory composition or directly stimulates the 
immune response, we stimulated bone marrow-derived macrophages (BMDM) in vitro with 
fecal content from SPF and SPF+P. intestinalis mice. Fecal contents were divided in two 
fractions, microbial community (pellet) and the secreted microbial factors (supernatant), and 
their potential to trigger IL-6 secretion in BMDM was determined. Strikingly, stimulation of 
WT BMDM with SPF+P. intestinalis microbial community resulted in higher levels of pro-
inflammatory response in comparison to SPF community alone (Figure 19A). Secreted 
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microbial factors stimulated the macrophages to a lesser degree and with no significant 
differences between the SPF and SPF+ P. intestinalis communities (Figure 19B). These 
data corroborate the in vivo effects of P. intestinalis on colonic inflammation during DSS 
colitis, and suggest that cell-associated, rather than secreted microbial factors in the SPF+P. 
intestinalis community are responsible for promoting an inflammatory response. To 
determine whether P. intestinalis alone can act directly immunostimulatory on the immune 
cells, we stimulated BMDM with P. intestinalis and compared it to Bacteroides acidifaciens, 
related Gram-negative intestinal commensal bacteria isolated from mice. BMDM stimulated 
with P. intestinalis resulted in two-fold increased production of IL-6 in comparison to 
stimulation with B. acidifaciens (Figure 19C). These results suggest that P. intestinalis has 
higher immunogenic properties than other Bacteroidales, which potentially contribute to an 
overall more robust immune activation by SPF+ P. intestinalis community in vitro and after 
damage to the intestinal barrier in vivo.  
 
Figure 19: Prevotella-containing community and P. intestinalis alone trigger higher   
IL-6 production via TLR4 recognition 
IL-6 measured from BMDM culture supernatant stimulated for 12 h with luminal contents collected 
from SPF and SPF+P. intestinalis mice. Luminal contents were normalized to 50 mg/ml and 
centrifuged (5 min, 10,000 rpm). WT and Tlr4
-/-
 BMDM were stimulated with sonicated and heat-
inactivated bacterial pellet (1:100 dilution) – `Microbial community` (A) or with undiluted supernatants 
- `Secreted microbial component` (B). IL-6 measured from BMDM culture supernatant stimulated for 
12 h with sonicated and heat-inactivated P. intestinalis and B. acidifaciens bacteria (C). Data shown 
as mean ± SEM, P values are determined by two-way ANOVA by Tukey´s multiple comparison 
analysis *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 0.0001 
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Next, we wanted to determine the major receptor contributing to stronger immune activation 
by P. intestinalis. Significant reshaping of the microbial composition and F/B ratio in SPF 
community by P. intestinalis colonization also significantly altered the ratio between Gram-
negative and Gram-positive bacteria, resulting in the domination of Gram-negative bacteria 
in SPF+P. intestinalis colonized mice (data not shown). We therefore investigated the role of 
Toll-like receptor (TLR) 4 recognizing bacterial lipopolysaccharide (LPS) present in the cell 
wall of Gram-negative bacteria in BMDM activation by P. intestinalis. Whereas both WT and 
Tlr4-/- BMDM stimulated with Prevotella-containing community showed higher IL-6 
production in comparison to SPF community, Tlr4-/- BMDM produced five-fold less IL-6 than 
the WT macrophages (Figure 19A). Even more strikingly, IL-6 production in BMDM in 
response to stimulation by P. intestinalis and B. acidifaciens was completely impaired in 
absence of TLR4 (Figure 19C). Together, these results provide evidence that P. intestinalis 
has the immunogenic potential to activate a pro-inflammatory immune response in a TLR4-
dependent manner, which is in line with the observed enhanced inflammation in vivo.  
4.6 P. intestinalis-induced decrease of IL-18 modulates the 
exacerbation of colonic inflammation  
Besides increased IL-6 secretion during DSS colitis, we also observed that P. intestinalis 
colonization of SPF mice resulted in a decrease of IL-18 levels in colonic tissue before 
induction of intestinal inflammation (Figure 12). The role of IL-18 during DSS colitis has 
been controversially discussed, either suggested to play a role in promoting intestinal 
epithelial integrity and protection from acute experimental colitis19,221,222, or to exacerbate 
intestinal inflammation due to impaired repair processes61,62. This prompted us to investigate 
whether lower levels of colonic IL-18 may be linked to the Prevotella-enhanced susceptibility 
to colonic inflammation during DSS-induced colitis.  
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4.6.1 Prevotella-induced decrease of Il18 gene expression and 
IL-18 production is associated with the decrease in acetate 
levels 
Distinct microbial metabolites, specifically SCFA, taurine, histamine, and polyamines, 
modulate inflammasome signaling on the transcriptional and post-transcriptional level46,63. 
Hence, we first wanted to address whether changes in IL-18 protein levels observed in 
Prevotella-colonized mice were accompanied by changes on the transcriptional level. 
Indeed, P. intestinalis colonization resulted in reduced Il18 expression, while Casp1 
expression was not significantly affected (Figure 20A). In addition we measured gene 
expression of AMPs which have been previously proposed, in particular Ang4 and Retnlb, 
were dependent on IL-18 production, we investigated whether different levels of IL-18 in 
SPF and SPF+P. intestinalis mice would result in differences of AMP expression. Notably, 
P. intestinalis colonization of SPF mice and downregulation of IL-18 production did not affect 
the gene expression of the antimicrobial peptides Ang4 and Retnlb in our microbiota 
composition, but rather induced the expression of Reg3g (Figure 20B). 
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Figure 20: Colonic gene expression in SPF and SPF+P. intestinalis mice 
Colonic Casp1 and Il18 (A) and antimicrobial peptides (B) gene expression in mice with SPF and 
SPF+P. intestinalis microbiota, 4-5 weeks after colonization. Data shown as mean ± SEM, and P 
values represent an unpaired nonparametric Mann-Whitney test *p < 0.05; **p < 0.01. 
 
 
Whereas taurine has been demonstrated to enhance IL-18 processing via activation of the 
Nlrp6 inflammasome, histamine and distinct polyamines have been shown to have an 
inhibitory effect46. We therefore, measured taurine, histamine, putrescine, spermine, 
spermidine, and cadaverine concentrations in cecal content of SPF and SPF+P. intestinalis 
mice, however, we did not observe any correlation between the relative amounts of detected 
metabolites and levels of IL-18 (Figure 21). Conversely, mice with SPF microbiota, which 
showed higher levels of colonic IL-18, displayed higher concentrations of putrescine than 
the Prevotella-colonized mice, while other metabolites showed no significant differences 
(Figure 21). These results demonstrate that P. intestinalis colonization is not increasing the 
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production of histamine, putrescine, and cadaverine, which have been shown to inhibit 
inflammasome activation. 
 
Figure 21: Analysis of IL-18-modulating metabolites in SPF and SPF+P. intestinalis 
mice 
Relative concentration of metabolites from cecal content of SPF and SPF+P. intestinalis mice 
analyzed by GC-MS in selective ion monitoring (SIM) mode. Data represent mean ± SEM, P values 
indicated represent an unpaired nonparametric Mann-Whitney test *p < 0.05; **p < 0.01. 
  
The role of SCFA in the maintenance of epithelial health has been extensively 
investigated63,159–161,165. Mackay and colleagues demonstrated that the SCFAs acetate and 
butyrate can act on GPR43 and GPR109a receptors on IECs, respectively, and stimulate 
the expression of the Il18 gene in the intestine63. Since we recently showed modulation of 
SCFA levels 8 weeks after Prevotella spp. colonization resulting in alterations of osteoclast 
metabolism in the bone170, we hypothesized that P. intestinalis also induced a decrease in 
SCFAs earlier after colonization and that this may result in distinct IL-18 production in SPF 
and SPF+P. intestinalis mice. Thus, we measured SCFAs concentrations in the cecal and 
colonic luminal content and serum in SPF and SPF+ P. intestinalis mice 4 weeks after 
Prevotella colonization revealing that total SCFAs levels were affected already at this time 
point (Figure 22). 
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Figure 22: Analysis of SCFAs in SPF and SPF+P. intestinalis mice 
Concentration of total SCFAs, butyrate, propanoate, and acetate in colon (A) and cecum content (B), 
and serum (C) of SPF and SPF+P. intestinalis mice after 4 weeks of colonization, analyzed by GC-
MS. Data represent mean ± SEM, P values indicated represent an unpaired nonparametric Mann-
Whitney test *p < 0.05; **p < 0.01; ***p< 0.001. 
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More specifically, we observed a significant decrease in total SCFAs concentration in 
colonic and cecal content of Prevotella-colonized mice with predominant decrease in the 
concentration of acetate, the most abundant SCFA (Figure 22A and 22B). While butyrate 
concentrations were not effected in colonic content (Figure 22A), we observed a significant 
increase in the cecum (Figure 22B). Whereas Prevotella colonization resulted in decrease of 
propionate concentration, its levels were increased in the cecal content. Even though 
concentration of systemic SCFAs measured in the serum was not significantly altered by 
Prevotella colonization, we observed a tendency of concentration decrease in total SCFAs 
and acetate (figure 22C). These results demonstrate a significant impact P. intestinalis on 
concentration of SCFAs in the intestine and suggest that the lower concentration of IL-18 in 
Prevotella-colonized mice is associated with changes in the concentration of acetate.  
4.6.2 Administration of rIL-18 attenuates colitis severity in 
mice colonized with P. intestinalis 
We finally sought to determine whether the Prevotella-aggravated intestinal inflammation 
and tissue damage in the DSS induced colitis model are linked to the observed decrease in 
colonic IL-18 production. Since both, acetate and IL-18, have been previously shown to 
ameliorate severity of DSS colitis46,63,158,223, we aimed to determine whether IL-18 
supplementation would be sufficient to reduce inflammation in Prevotella-colonized mice. 
After 5 weeks of P. intestinalis colonization, SPF and SPF+P. intestinalis mice were 
administered daily with recombinant IL-18 (rIL-18) or a vehicle intraperitoneally (i.p.) starting 
two days prior and during the DSS colitis. Indeed, administration of rIL-18 attenuated colitis 
severity in mice colonized with P. intestinalis, as assessed by reduced weight loss (Figure 
23A and 23B) and histological examination of colon sections performed on day 7 post DSS 
induction (Figure 23C and 23D). While both SPF mice groups, receiving PBS and rIL-18, 
showed similar mild crypt erosion, Prevotella-colonized mice administered with rIL-18, but 
not PBS, showed diminished colitis severity. Prevotella-colonized mice injected with PBS 
displayed more severe epithelial hyperplasia and mucosal invasion of inflammatory cells in 
comparison to mice supplemented with rIL-18 (SPF+P.intestinalis+rIL-18) (Figures 23C). 
Together, these results demonstrate that Prevotella-induced suppression of colonic IL-18 
production alters susceptibility to intestinal inflammation upon tissue damage.  
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Figure 23: rIL-18 supplementation ameliorates Prevotella-induced exacerbation of 
colonic inflammation 
Body weight loss of SPF and SPF+P. intestinalis mice during DSS colitis, either treated with PBS or 
200 ng rIL-18 (A). Percent body weight (B) and histological evaluation of colon tissue (C-D) on day 7 
of DSS colitis of mice with representative images of H&E stained distal colon sections (day 7) (C). 
Data shown as mean ± SEM from two pooled experiments. P values are determined by two-way 
ANOVA by Tukey´s multiple comparison analysis *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 0.0001. 
 
It has been previously demonstrated that IL-18 plays an important role in shaping the 
intestinal microbiome and preventing dysbiosis by regulation of AMPs production46.  In order 
to investigate whether rIL-18 supplementation had an impact on microbiota composition, we 
compared the microbial communities of SPF and SPF+P. intestinalis mice before and after 
rIL-18 treatment. The permutational multivariate analysis of variance (ADONIS) showed 
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significant differences between the experimental groups are attributed to Prevotella-induced 
alterations in the microbiota (R2 = 0.53, p<0.001), but not rIL-18 treatment (R2 = 0.09, 
p<0.01) (Figure 24A and 24B). These data suggest that diminished colitis severity in rIL-18 
treated SPF+P. intestinalis mice is not an effect of IL-18 on microbiota composition, but 
rather a direct effect of IL-18 on the intestinal epithelium. 
 
Figure 24: Impact of rIL-18 treatment on microbiota composition of SPF and SPF+P. 
intestinalis mice   
Analysis of β-diversity (PCoA) along with multivariate analysis of variance of variables ‘microbiota’, 
‘genotype’ and ‘cage’ (A) and fecal microbiota composition, before and 1 day after rIL-18 treatment in 
SPF and SPF+P. intestinalis mice  using 16S rRNA gene. P values are determined by ADONIS test 
*p < 0.05; **p < 0.01; ***p< 0.001. 
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Intestinal homeostasis is maintained by the dynamic interplay between the gut microbiota 
and the host immune system224. Besides a wide range of metabolic functions and protection 
against enteric pathogens, the gut microbiota plays a crucial role in shaping the host 
immunity by direct interactions with the host cells or via the production of diverse 
metabolites, such as short-chain fatty acids, polyamines, adenosine triphosphate (ATP), and 
numerous others145. Positioned between the microbiota and the cells of the immune system, 
intestinal epithelial cells, including goblet cells and Paneth cells, serve not only as a passive 
barrier but also as a source of antimicrobial substances strengthening the barrier42. 
Moreover, in response to gut microbes and their metabolites, intestinal epithelial cells 
produce mediators such as cytokines and chemokines that impact not only the functioning of 
the epithelial barrier but as well determine the balance between regulatory and pro-
inflammatory immune responses in the intestine. In other words, compositional and 
metabolic changes in the gut microbiota have the potential for a significant impact on the 
intestine, some of them shifting the intestinal homeostasis and contributing to the 
development of intestinal inflammation30. Moreover, perturbations in the microbial 
composition have been as well linked with profound impact on the host systemic immune 
system with far-reaching consequences contributing to various autoimmune and 
inflammatory disorders i.e. rheumatoid arthritis99, multiple sclerosis225, asthma, and allergic 
disease226,227. 
As it became clear that the members of the microbiota have a significant impact on the 
modulation of the immune responses, their role in the development of inflammatory and 
autoimmune diseases has been the focus of numerous studies. Both in humans and animal 
models, studies have established associations between the alterations in the microbiota
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composition and a wide range of local and systemic inflammatory diseases. In the case of 
inflammatory bowel disease, it is hypothesized that the development of the disease is a 
result of dysregulated immune responses towards the intestinal microbiota1,29, but different 
concepts about how the microbiota promotes inflammation are debated. Accordingly, an 
overall loss of microbial diversity, changes in the balance between beneficial commensals 
and potential pathobionts as well as changes in microbial metabolites such as SCFAs have 
been reported in patients and are hypothesized to promote IBD development89–91. Still, the 
exact identity of intestinal bacteria and their metabolites that trigger aberrant host responses 
and contribute to the development of IBD and other autoimmune diseases in humans are 
not exactly known. Comparison of healthy with disease state without clearly demonstrating 
the causality is still a major issue in the field of microbiota research as the direct causal 
relationship between microbiota and complex diseases has been difficult to prove outside 
animal models.  For instance, several studies in humans described associations between 
IBD and increased abundance in Gammaproteobacteria and presence of 
Enterobacteriaceae, particularly adherent-invasive E. coli (AIEC) strains92. Notably, AIEC 
modulate colitis susceptibility in some mouse models228,229 and additional members of the 
Enterobacteriaceae family, i.e. Klebsiella pneumoniae and Proteus mirabilis were also 
identified to promote colitis in mice94,95. Moreover, several other members of the murine 
microbiota were identified to directly exacerbate intestinal inflammation. This includes 
Akkermansia muciniphila96 as well as distinct Bacteroides97 and Helicobacter species 98. 
Beyond these well-studied examples, microbiome studies have identified many microbes 
that were found enriched in disease-promoting communities, but with unknown roles in host-
microbiota crosstalk, i.e. members of the Prevotella genus18,99. 
The role of members of the Prevotella genus within the intestinal microbiota and their effects 
on the host is not completely understood and somewhat conflicting interpretations have 
been reported. Specifically, the increased relative abundances of members of 
Prevotellaceae family within diverse microbial ecosystems have been associated with 
rheumatoid arthritis 99,230, periodontitis231, and intestinal and vaginal dysbiosis18,232–234. While 
some studies observed the increased abundance of Prevotella in the gut microbiota of IBD 
patients143,144, others showed no association91. Contrary, members of the genus Prevotella 
have also been associated with beneficial effects on the health as well, such as improved 
glucose metabolism139 and being largely abundant in the gut microbiota of individuals that 
consume plant-rich diet136,137. The reasons for these seemingly opposing effects by 
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Prevotella on the host´s physiology are not clear. Importantly, these effects may not be 
causally linked to the presence of Prevotella as the direct functional relevance of increased 
Prevotella colonization has not yet been causally demonstrated. These distinct host 
responses to Prevotella spp. may be in part explained by high species diversity and 
potentially different functional capabilities (Gupta et al., 2011). So far mechanistic studies 
demonstrating a potential disease-triggering role for Prevotella spp. have been largely 
limited by the restricted availability of diverse intestinal Prevotella isolates, including those 
from model organisms such as the mouse.  
Altogether, these findings highlight the interest to expand our understanding of the impact of 
Prevotella spp. on the intestinal ecosystem and the host and the need for more studies that 
investigate the immunomodulatory properties of Prevotella spp. and their potential 
mechanisms. However, as of now, public culture collections include three Prevotella isolates 
from the human intestine, while no species isolated from mice are available. With the aim to 
study the role of Prevotella spp. in the intestine and whether they have the ability to promote 
intestinal inflammation we attempted to isolate distinct Prevotella species from mouse with 
increased susceptibility to DSS colitis. Phylogenetic analysis of the bacterial isolates 
demonstrated we cultivated three novel Prevotella species. Based on their niche and host 
specificity, the following names Prevotella intestinalis, Prevotella rodentium, and Prevotella 
muris were proposed. Strikingly, all species colonized the WT SPF mice in high relative 
abundance suggesting lack of competition and high in vivo fitness. We also revealed that 
the three species may have a very similar niche in the intestine, as they demonstrated 
interspecies competition, with P. intestinalis displaying the highest in vivo fitness. Genomic 
analysis of the Prevotella isolates by another scientist in the group, Eric J.C. Galvez, 
suggests the interspecies competition may be a result of their distinct genomic potential and 
capability to utilize dietary polysaccharides. To further study the role of Prevotella on the 
intestinal ecosystem and the intestinal health, we selected P. intestinalis as representative 
species based on its highest phylogenetic similarity to P. copri, human intestinal species, 
and their in vivo fitness. 
Detailed biogeography analysis of P. intestinalis colonization in SPF mice revealed its 
highest relative abundance in the luminal content of colon and cecum. Confirming the 
previous finding on the Prevotella niche, we demonstrated its presence in both the lumen as 
well as the mucus layer210,211. Notably, due to proximity to the tissue, mucosa-associated 
bacteria are thought to play a decisive role in stimulating local and systemic immune 
  Discussion 
 
 
90 
 
responses29,236. Further analysis of the impact that P. intestinalis colonization has on the 
resident microbial ecosystem of SPF mice revealed significant reshaping of the microbiota 
composition, resulting in the decrease of α-diversity and members of the Firmicutes phylum. 
Interestingly, both changes have been previously attributed to dysbiosis and microbiota of 
IBD, asthma, and rheumatoid arthritis patients237–239. Cytometric enumeration showed that 
the number of bacterial cells in the SPF microbiota was not altered by Prevotella 
colonization suggesting P. intestinalis does not only colonize previously unoccupied niche 
but indeed alters the community structure.  
Presence of members of the Prevotellaceae family has been identified by 16S rRNA gene 
sequencing in mice prone to intestinal inflammation18,67. However, a causal relationship 
between the presence of Prevotella spp. and intestinal inflammation has not yet been 
causally demonstrated. In the present work we wanted to examine whether P. intestinalis, 
previously associated with increased susceptibility to chemically induced colitis in Nlrp6-/- 
mice, has the potential to promote intestinal inflammation. Colonization by P. intestinalis did 
not spontaneously lead to the inflammation in the intestine of immunocompetent mice (up to 
5 weeks of colonization). Ability of P. intestinalis to induce intestinal inflammation 
spontaneously should be further considered in more suitable spontaneous colitis models 
such as Muc2- and Il10-deficient mice, both having a defective mucus barrier and 
developing inflammation in response to luminal bacteria190. However, upon induction of the 
damage to the intestinal barrier and exposure to the luminal bacteria in the DSS colitis 
model, Prevotella-colonized mice displayed signs of exacerbated inflammation in 
comparison to SPF mice. Increased inflammation induced by Prevotella colonization was 
largely present in the colon area. Despite similarly high relative abundance of P. intestinalis 
in the cecum and colon, we did not observe higher inflammation in the cecum of SPF+P. 
intestinalis when compared to the SPF mice. These findings are rather an effect of the DSS 
colitis model that is known to predominantly influence the epithelial barrier in the colon, and 
not the cecum190. Specifically, the inflamed tissue of mice colonized with P. intestinalis was 
characterized by increased levels of IL-6 and TNF-α, as well as higher levels of neutrophil-
attracting chemokines accompanied with neutrophils infiltration. Strikingly, while the 
intestinal community of Nlrp6-deficient mice, from which P. intestinalis was isolated, 
exacerbates DSS-colitis in a T-cell dependent manner67, P. intestinalis did not require 
adaptive immune cells to exacerbate disease, i.e. Rag2-deficient mice showed Prevotella-
exacerbated intestinal inflammation. In addition, analysis of host transcriptome in colonic 
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tissue suggested that Prevotella colonization may induce differentiation and activation of B 
cells, however immune phenotyping and use of transgenic mice revealed no relevance of B 
cells for increased susceptibility to intestinal inflammation in Prevotella-colonized mice. 
These results suggest that other members, or combined effects of distinct microbes in the 
colitogenic community in Nlrp6-/- mice are responsible for induction of pro-inflammatory 
adaptive immune cells. 
Our data clearly demonstrate that Prevotella colonization shapes host immunity even during 
the steady state, i.e. enhanced expression of antimicrobial peptide RegIIIγ and reduction of 
IL-18 production. RegIIIγ is an antimicrobial peptide produced by enterocytes in the colon 
and Paneth cells in the small intestine240. It has been shown to play an important role in 
limiting microbiota interaction with the epithelial layer. Interestingly, previous work suggested 
that RegIIIγ selectively targets Gram-positive bacteria in the intestine241, although it has 
been shown that lipopolysaccharide, a TLR4 ligand in Gram-negative bacteria, is sufficient 
to elicit a dose-dependent expression of RegIIIγ in germ-free mice45. Whether P. intestinalis 
only triggers the RegIIIγ colonic expression or its activity is also targeted against Prevotella 
remains unclear. To address this question, one could compare the numbers of bacteria 
before and after treating the P. intestinalis culture with recombinant RegIIIγ. Other possibility 
would be to compare the abundances of P. intestinalis in WT and RegIIIγ-deficient mice in 
vivo. 
As mentioned, we also observed a significant decrease of colonic Il18 expression and IL-18 
production during steady state in P. intestinalis-colonized mice. Hence, we hypothesized 
that these changes affected the intestinal barrier during steady state, which in turn 
contributed to a more severe intestinal inflammation in Prevotella-colonized mice during 
DSS colitis. Indeed, rIL-18 supplementation ameliorated the susceptibility to intestinal 
inflammation in Prevotella-colonized mice and alleviated colonic tissue damage. Notably, 
even though IL-18 has been widely studied, no definitive role of IL-18 in intestinal 
homeostasis and inflammation has been conclusively established. While some studies 
suggested IL-18 has a protective role, preventing dysbiosis18,46 and promoting epithelial 
barrier integrity and regeneration19,63, others have linked IL-18 to increased colitis 
severity61,62. One potential explanation for the reported differences was proposed by 
Sigmund suggesting that the cellular source of IL-18 and its temporal spatial expression 
might be of crucial importance49. Constitutively expressed IL-18 in the epithelial cells may 
have a protective role contributing to the maintenance of the intestinal barrier by enhancing 
  Discussion 
 
 
92 
 
the regeneration of the damaged epithelium. In turn, IL-18 produced by the macrophages in 
response to the microbial products after damage to the barrier may promote inflammation49. 
This hypothesis has been tested by Nowarski et al whose work showed that irrespective of 
cellular source IL-18 exacerbates intestinal inflammation as its deletion in both IECs and 
hematopoietic cells ameliorates intestinal inflammation in DSS colitis model62. Our data 
further add to the complex role of IL-18 in the intestine during homeostasis and inflammation 
suggesting that balanced levels of IL-18 are required to promote the intestinal homeostasis 
and contain intestinal inflammation.  
A significant part of the interplay between the host and the microbiota is mediated in part via 
microbiota-derived metabolites. While for the majority of metabolites it is not known if or how 
they could affect the host´s immune system, in the last two decades a small number of 
diverse metabolites with immunomodulatory properties have been described145. Several 
microbiota-derived metabolites in the intestine have shown the ability to modulate IL-18 
production, either by effecting Il18 expression164,165 or through modulation of inflammasome 
activation46,63. We analyzed distinct metabolites known to modulate Il18 expression, 
including polyamines, histamine, taurine, and SCFAs, and identified that colonization of SPF 
community by P. intestinalis is accompanied with a significant decrease in SCFAs levels, in 
particular acetate. Interestingly, we observed increased concentration of butyrate in the 
cecum of Prevotella-colonized mice, while no differences were detected in the colon. The 
reasons for these differences remained unclear. The observed decrease in SCFAs 
concentration is in line with our previous reports demonstrating the ability of distinct 
Prevotella spp. to alter the concentration of SCFAs locally and systemically after extend 
periods of time170. In general, SCFAs have been linked with anti-inflammatory properties in 
the intestine, namely promoting regulatory immune responses159,161 and strengthening the 
epithelial barrier242,243. As an end product of microbial fermentation of dietary fiber, intestinal 
production of SCFAs, specifically straight-chain SCFAs, is firmly dependent on the diet and 
the microbiota composition. As both SPF and SPF+P. intestinalis received the same 
standard chow diet, changes in the total SCFAs and acetate in our experiments were 
independent of diet and linked only to Prevotella colonization.  
Members of Clostridia and Bacteroidetes have been reported to be the main producers of 
SCFAs244. While production of butyrate has been associated to Clostridia, members of the 
Bacteroidetes have been reported to be the major contributor to acetate production149,150. 
Surprisingly, Prevotella-induced microbiota changes in SPF mice resulted in a decrease, 
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rather than the expected increase of acetate concentration in SPF mice. Whether lower 
concentration of SCFAs in mice colonized with Prevotella is a result of the decreased 
abundance of SCFA producers or reflects a consumption of acetate by P. intestinalis 
remains to be investigated. Nevertheless, these data suggest that Prevotella spp. play an 
important role in the modulation of SCFA production, either by reduction of beneficial SCFA-
producing bacteria or by direct effects on acetate. Decreases in SCFAs, including acetate, 
as consequences of dietary interventions have been previously linked to changes in IL-18 
production as well as increased colitis severity63, suggesting that changes in IL-18 
concentration in SPF+P. intestinalis mice are a result of the Prevotella-induced decrease in 
acetate levels. Notably, patients with ulcerative colitis have been previously reported to have 
a decrease in numbers of SCFA-producing bacteria106, and treatment of patients with SCFA 
enema has been shown to ameliorate colonic inflammation154. Whether increasing acetate 
concentration in Prevotella-colonized mice, either by supplementation in drinking water or 
providing high-fiber diet, would relieve the intestinal inflammation remained undetermined. 
The concern about preforming these experiments lies in the fact that P. intestinalis are 
highly sensitive to dietary change and introducing semisynthetic diets high in fiber 
diminishes their relative abundance in the intestine (data not shown). Furthermore, 
supplementation of acetate in the drinking water of mice is likely not to reach the large 
intestine in high concentration as most of it is being absorbed by the intestinal cells of the 
upper gastro-intestinal tract. In addition, potential explanation for different susceptibility to 
intestinal inflammation in SPF and SPF+P. intestinalis mice may be due to the effects of 
acetate on tight junctions between epithelial cells242. Whether decrease of acetate 
downregulates tight junctions resulting in increased intestinal permeability of SPF+P. 
intestinalis mice, would be worthwhile to further investigate by testing the intestinal leakiness 
or difference in TJ protein expression in SPF and SPF+P. intestinalis mice.  
In addition to altered SCFA profiles that predispose the host to inflammation, P. intestinalis 
and reshaping of the SPF community may also cause directly enhanced immune activation. 
Stimulation of BMDM with P. intestinalis alone induced IL-6 production, which required 
recognition of P. intestinalis by TLR4. Interestingly, another related Gram-negative bacteria, 
i.e. B. acidifaciens, also induced IL-6 production in macrophages, but to a lesser degree, 
suggesting that P. intestinalis and potentially other members of the genus Prevotella 
differently affect immune activation via TLR4. Notably, TLR4 mutations are associated with 
IBD245, and upregulation of TLR4 expression has been reported in the intestine of IBD 
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patients246. Additionally, it has been previously reported that LPS immunogenicity in Gram-
negative members of the gut microbiota varies and it can either promote maintenance of 
homeostasis or induce inflammation247,248. While members of the Bacteroidales order, a 
predominant Gram-negative bacteria of the gut microbiota, have been shown to produce 
antagonistic forms of LPS (tetra- or penta-acylated), driving immune silencing247, LPS of 
Enterobacteriaceae (hexa-acylated) has the ability to promote inflammation due to 
acetylation pattern of its lipid A248. Interestingly, a less immunogenic, antagonistic forms of 
LPS in Bacteroides species have been suggested to influence the susceptibility of children 
to allergies and autoimmunity due to inability to provide signals necessary in early life for 
maintenance of mucosal homeostasis249. These data suggest that nature and acetylation 
pattern of different LPS subtypes largely determine the level of immune activation triggered 
by the microbe-derived LPS. Finally, the relative contribution of the pro-inflammatory 
capabilities of Prevotella to the exacerbated intestinal inflammation, including LPS structure 
remains to be characterized.   
Whether other intestinal Prevotella isolates would demonstrate a similar impact on the 
microbial community and immunomodulatory effects in the host remained to be investigated. 
Notably, recent studies demonstrated that assignment of bacteria to a specific family or a 
genus does not predict immunological properties of the entire taxonomic level, highlighting 
the importance of identifying the properties at the species or even the strain level as it is 
done already for pathogens215,250. In particular, genomic analysis of available Prevotella 
species from distinct mucosal sites within human body has demonstrated high diversity with 
a small shared core genome and adaptation to a specific anatomic niche235. This may 
explain why Prevotella is abundant in the healthy microbiota, suggesting that only certain 
strains may exhibit pathobiont properties. Given the amount of opposing reports on 
Prevotella spp. impact on the host physiology, it may be necessary in the future to consider 
species and even strains variability in order to advance our understanding of beneficial and 
detrimental roles Prevotella species play in health and disease.  
Taken together, our data provide strong evidence for an immunomodulatory role of 
Prevotella spp. in the intestine. We identified that colonization by a novel member of the 
Prevotella genus significantly decreased the production of the bacterial fermentation product 
SCFAs and the immunomodulatory cytokine IL-18, which is associated to an increase in the 
severity of intestinal inflammation. Our experimental evidence suggests that Prevotella-
mediated intestinal injury may be the influenced via different pathways, yet, the ability to 
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ameliorate Prevotella-induced disease severity by supplementation of IL-18 suggests that 
remodeling the microbial metabolome and specifically SCFA production by P. intestinalis 
may be the dominating pathomechanism. Finally, the consequences of modulation of SCFA 
production in the intestine by Prevotella spp. may have far-reaching consequences for the 
host, as SCFA have immunomodulatory effects in distant sites such as the liver, bones or 
the brain.  
 
Figure 25: Impact of P. intestinalis colonization in intestinal homeostasis and 
inflammation 
Microbiota-derived enzymatic activities generate metabolites such as SCFAs from dietary fiber. 
SCFAs, including acetate, can trigger intestinal epithelial cells to produce cytoprotective IL-18. 
Colonization of P. intestinalis results in increased expression of the AMP RegIIIγ and the decreased 
levels of acetate that has been associated with lower levels of colonic IL-18. Modulation of IL-18 
production during steady state has been linked to increased susceptibility to intestinal inflammation in 
Prevotella-colonized mice. Prevotella-induced intestinal inflammation is mediated by higher leukocyte 
infiltration, in particular, neutrophils. In addition, P. intestinalis directly enhanced immune activation 
via TLR4 recognition. 
 
  Discussion 
 
 
96 
 
Finally, one of the remaining challenges in the microbiota research field is moving from 
observations and correlation studies to mechanistic studies that will improve our 
understanding of the immune-modulating effects of specific bacteria. Isolation and culturing 
of the intestinal microbes is a crucial step in performing these studies. Availability of diverse 
bacterial species and strains as well as the identification of mechanisms of their interaction 
with the host have a great value in the future development of therapeutics and would 
ultimately allow manipulation of these interactions for health benefits. Besides already 
available fecal microbiota transplantation, precise microbiota manipulation with selected 
beneficial bacteria may be more effective and safer treatment for distinct autoimmune 
disorders, inflammatory diseases, and enteric infections. Further characterization of the 
cellular and molecular mechanism of microbe-host interactions might in the future identify 
molecules that would mimic the desirable immune effects instead of relying on the 
colonization. These include microbiota-derived metabolites, such as SCFAs, which have 
been shown to provide important signals that shape local and systemic immune responses.  
Considering the impact of the diet on the microbiota and metabolite milieu in the intestine, 
manipulation of the microbial composition and function by diet change may become a 
relevant complementary therapeutic approach. Even though much work still needs to be 
done to improve our understanding of the microbiota modulation of the immune responses, 
the journey is worthwhile if one considers the therapeutic opportunities that lie within the 
microbiota-based treatments of various inflammatory and infectious diseases. 
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